US Pat. No. 11,064,644

LIQUID MANURE SPREADER


1. A liquid manure spreader comprising:a central spreader arm and
two lateral spreader arms pivotably disposed thereon, which are pivotable in a first direction between a position aligned with the central spreader arm and a position oriented transversely to the central spreader arm,
wherein the central spreader arm is pivotable around at least one transverse axis between a downwards folded working position and an upwards folded transport position, the central spreader arm being pivotable in a second direction that is transverse to the first direction;
wherein the at least one transverse axis is translationally movably guided between a lower position and an upper position in at least one elongated hole extending in a vertical direction of the liquid manure spreader, the transverse axis extending through and being movable within the at least one elongated hole between the lower position and the upper position.

US Pat. No. 11,064,643

IMPLEMENT TOOL ANGLE CONTROL SYSTEM


1. An agricultural implement, comprising:a plurality of ground-engaging tools configured to modify a surface configuration of an agricultural field;
a hydraulically-controlled subsystem configured to modify an operating angle of the plurality of ground-engaging tools, the hydraulically-controlled subsystem comprising:a fluidic pathway configured to receive a flow of hydraulic fluid;
a first and a second serially plumbed hydraulic actuator configured to receive the flow of hydraulic fluid from the fluidic pathway to drive movement of one or more of the plurality of ground-engaging tools; and
a first correction valve coupled to the second serially plumbed hydraulic actuator to provide an additional flow of hydraulic fluid to the second serially plumbed hydraulic actuator to drive movement of the second serially plumbed hydraulic actuator relative to the first serially plumbed hydraulic actuator;

a sensor coupled to the hydraulically-controlled subsystem configured to generate sensor signals indicative of a current operating angle of the plurality of ground-engaging tools; and
an implement control system configured to receive the sensor signals from the sensor to determine the current operating angle of the plurality of ground-engaging tools, and, upon determining the current operating angle is to be changed to a new operating angle, generate control signals for the hydraulically-controlled subsystem to modify the operating angle of the plurality of ground-engaging tools from the current operating angle to the new operating angle.

US Pat. No. 11,064,642

AGRICULTURAL SHANK WITH PROTECTED SOIL SENSOR

CNH Industrial Canada, Lt...


1. An agricultural implement, comprising:a chassis; and
a shank carried by the chassis, the shank including:a shank body configured to penetrate a soil top surface;
an optical sensor attached to an outer lateral surface of the shank body, wherein the optical sensor includes a window, at least a portion of the window is positioned laterally outward from the outer lateral surface of the shank body, the window enables a signal emitted by the optical sensor to contact soil adjacent to the window, and the optical sensor defines a probing area adjacent to a lateral side of the shank body; and
a sensor shield carried by the shank body and positioned at least partially in front of the optical sensor, wherein a portion of the sensor shield is positioned against the window of the optical sensor, the sensor shield is configured to deflect oncoming soil flow away from the optical sensor without substantially disrupting soil flow into the probing area, and the sensor shield extends laterally past the outer lateral surface of the shank body, such that an outer lateral edge of the sensor shield is flush with an outer lateral end of the window.


US Pat. No. 11,065,265

COMPOSITIONS OF FOSAPREPITANT AND METHODS OF PREPARATION

SPES PHARMACEUTICALS INC....


1. A stable, liquid composition comprising:fosaprepitant or a pharmaceutically acceptable salt thereof;
at least one pharmaceutically acceptable derivative of ?-cyclodextrin;
a pharmaceutically acceptable carrier;
a pH adjusting agent;
wherein the composition does not contain polysorbate 80;
wherein a weight ratio of the fosaprepitant or a pharmaceutically acceptable salt thereof to the at least one pharmaceutically acceptable derivative of ?-cyclodextrin is about 1:10 to about 1:255; and
wherein a stability of the stable, liquid composition is maintained for at least three months at 25° C.

US Pat. No. 11,069,907

FUEL CELL SYSTEM AND METHOD FOR CONTROLLING FUEL CELL SYSTEM

NISSAN MOTOR CO., LTD., ...


1. A fuel cell system comprising:a fuel cell;
a fuel treating unit configured to treat raw fuel and generate fuel gas for the fuel cell;
an oxidant-gas heater configured to heat oxidant gas for the fuel cell;
a combustor configured to combust the raw fuel and generate combustion gas to heat the fuel treating unit and the oxidant-gas heater;
a first fuel injector configured to adjust a flow rate of the raw fuel supplied to the fuel treating unit;
a second fuel injector configured to adjust a flow rate of the raw fuel supplied to the combustor; and
a control unit configured to control the first fuel injector and the second fuel injector, wherein the control unit is configured to:
execute warming-up of the fuel cell by controlling the first fuel injector and the second fuel injector, and
execute rated operation of the fuel cell wherein rated operation is a power generation of the fuel cell for supplying power to an external device executed by activating the first fuel injector and stopping the second fuel injector after warming-up of the fuel cell;
wherein the control unit is configured to:
set a raw-fuel total flow rate of the flow rate of the raw fuel for the first fuel injector and the flow rate of the raw fuel for the second fuel injector during warming-up of the fuel cell such that the raw-fuel total flow rate is greater than the flow rate of the raw fuel in the first fuel injector during rated operation,
set the flow rate of the raw fuel for the second fuel injector to the raw-fuel total flow rate while the first fuel injector is set to be stopped before the fuel treating unit reaches an operable temperature of the fuel treating unit, and
set the flow rate of the raw fuel for the first fuel injector and the flow rate of the raw fuel for the second fuel injector such that the sum of the flow rate of the raw fuel for the first fuel injector and the flow rate of the raw fuel for the second fuel injector is set to be the raw-fuel total flow rate when the fuel treating unit reaches the operable temperature of the fuel treating unit.

US Pat. No. 11,065,266

METHOD OF TREATING MELANOMA USING AN INHIBITOR OF AN ATYPICAL PROTEIN KINASE C

UNIVERSITY OF SOUTH FLORI...


1. A method of treating a melanoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of an atypical protein kinase C (aPKC),wherein the aPKC inhibitor is 2-acetyl-1,3-cyclopentanedione (ACPD).

US Pat. No. 11,065,267

LYSOPHOSPHATIDYLCHOLINE COMPOSITIONS

Aker BioMarine Antarctic ...


1. A marine lysophosphatidylcholine (LPC) composition characterized in comprising from about 20% to about 100% LPC w/w of the composition and an omega-3 fatty acid content of from 5% to 50% w/w of the composition, a ratio of EPA:DHA of from 1:1 to 3:1 on a w/w basis or a ratio of DHA:EPA of from 1:1 to 5:1 on a w/w basis, and a 2-LPC:1-LPC ratio of from 1:8 to 18:1 on a w/w basis.
US Pat. No. 11,065,268

METHOD OF PREVENTING DIARRHOEA

CLASADO RESEARCH SERVICES...


1. A method of reducing the incidence of traveler's diarrhoea in a human, comprising orally administering daily to said human an effective amount of a composition comprising a mixture of galactooligosaccharides wherein the mixture of galactooligosaccharides comprises disaccharides Gal (? 1-3)-Glc; Gal (? 1-3)-Gal; Gal (? 1-6)-Gal; Gal (a 1-6)-Gal; trisaccharides Gal (? 1-6)-Gal (? 1-4)-Glc; Gal (? 1-3)-Gal (? 1-4)-Glc; tetrasaccharide Gal (? 1-6)-Gal (? 1-6)-Gal (? 1-4)-Glc and pentasaccharide Gal (? 1-6)-Gal (? 1-6)-Gal (? 1-6)-Gal (? 1-4) Glc for a period of seven days prior to departure and each day during travel away from home, wherein the effective amount of the composition comprises 2.7 g of the galactooligosaccharides in 5.5 g of the composition, and wherein the composition is administered as a single daily dose.
US Pat. No. 11,065,269

METHOD OF USING ASTAXANTHIN FOR THE TREATMENT OF DISEASES, AND MORE PARTICULARLY, THE TREATMENT OF CANCER


1. A method of treating a subject afflicted with an inflammatory disease, the method comprising:preparing glucosidic astaxanthin by reacting astaxanthin with a monosaccharide at a microwave frequency of between 1 and 100 GHz for at least one second and no more than twenty-five seconds; and
administering a therapeutic amount of the glucosidic astaxanthin to the subject in need of such treatment.

US Pat. No. 11,065,788

METHOD FOR MANUFACTURING GLOVES

ZEON CORPORATION, Tokyo ...


1. A method for producing a glove, comprising:a step of forming a dip-molded layer by dip-molding a latex composition containing a latex of a carboxyl group-containing conjugated diene rubber (A) that does not have an isoprene-derived monomer unit, and a metal compound (B) including a divalent or higher metal; and
a step of irradiating the dip-molded layer with ?-rays so as to cross-link a carbon-carbon double bond moiety of a conjugated diene monomer unit of the carboxyl group-containing conjugated diene rubber (A),
wherein the carboxyl group-containing conjugated diene rubber (A) is at least one selected from the group consisting of a carboxyl group-containing nitrile rubber (a1), a carboxyl group-containing styrene-butadiene rubber (a2), and a carboxyl group-containing butadiene rubber (a3),
wherein the carboxyl group-containing nitrile rubber (a1) is obtained by copolymerizing a monomer mixture containing a conjugated diene monomer, an ethylenically unsaturated carboxylic acid monomer, and an ethylenically unsaturated nitrile monomer, and is substantially free from an isoprene-derived monomer unit,
wherein the carboxyl group-containing styrene-butadiene rubber (a2) is obtained by copolymerizing a monomer mixture containing 1,3-butadiene, an ethylenically unsaturated carboxylic acid monomer and styrene, and is substantially free from an isoprene-derived monomer unit, and
wherein the carboxyl group-containing butadiene rubber (a3) is obtained by copolymerizing a monomer mixture containing a conjugated diene monomer and an ethylenically unsaturated carboxylic acid monomer, and is substantially free from an isoprene-derived monomer unit.

US Pat. No. 11,066,564

AQUEOUS PIGMENT DISPERSION

KAO CORPORATION, Tokyo (...


1. A water-based pigment dispersion comprising a polymer dispersant and a pigment, the polymer dispersant being prepared by crosslinking a carboxy group-containing water-insoluble polymer (A) with a water-insoluble polyfunctional epoxy compound,in which carboxy groups of the water-insoluble polymer (A) are at least partially neutralized by an alkali metal compound, and an acid value, a neutralization degree and a crosslinking degree of the neutralized water-insoluble polymer (A) satisfy the following conditions 1 to 3:
Condition 1: a value calculated according to the formula:{[100?(neutralization degree)?(crosslinking degree)]/100}×[acid value of


water-insoluble polymer (A)],is not less than ?30 mgKOH/g and not more than 30 mgKOH/g;
Condition 2: a value calculated according to the formula:[(neutralization degree)/100]×[acid value of water-insoluble polymer(A)],

is not less than 80 mgKOH/g and not more than 180 mgKOH/g; and
Condition 3: a value calculated according to the formula:[(crosslinking degree)/100]×[acid value of water-insoluble polymer(A)],

is not less than 80 mgKOH/g and not more than 180 mgKOH/g,
wherein the neutralization degree means a percent ratio (mol %) of a mole equivalent number of the alkali metal compound to a mole equivalent number of the carboxy groups of the water-insoluble polymer (A) [(mole equivalent number of alkali metal compound)/(mole equivalent number of carboxy groups of water-insoluble polymer (A))], and the crosslinking degree means a percent ratio (mol %) of a mole equivalent number of epoxy groups of the water-insoluble polyfunctional epoxy compound to a mole equivalent number of the carboxy groups of the water-insoluble polymer (A) [(mole equivalent number of epoxy groups of water-insoluble polyfunctional epoxy compound)/(mole equivalent number of carboxy groups of water-insoluble polymer (A))].

US Pat. No. 11,069,136

PRE-OPERATIVE SIMULATION OF TRANS-CATHETER VALVE IMPLANTATION

FEops NV, Ghent (BE)


1. A computer-implemented method for evaluating the placement of a prosthetic device in a patient's body, comprising:obtaining a plurality of digital images of a patient's cardiac anatomy;
obtaining a digital model of a prosthetic cardiac device;
generating, from the plurality of digital images, a patient-specific digital depiction of the patient's cardiac anatomy including a cardiac anatomical structure in fluid communication with an adjacent anatomical structure, using a computer system;
virtually placing the digital model of the prosthetic cardiac device within the cardiac anatomical structure of the patient-specific digital depiction;
calculating, using the computer system, a measure of blood flow obstruction to the adjacent anatomical structure of the patient-specific digital depiction resulting from the placement of the digital model of the prosthetic cardiac device; and
generating, using the computer system, information to indicate the measure of blood flow obstruction to the adjacent anatomical structure of the patient-specific digital depiction resulting from the placement of the digital model of the prosthetic cardiac device.

US Pat. No. 11,066,565

ALIPHATIC CERAMICS DISPERSANT

Lubrizol Advanced Materia...


1. A process for digitally printing on ceramic article or glass article substrate using an ink jetted through a nozzle by:a) providing a mixed metal oxide dispersed in a continuous hydrocarbon medium with a dispersing agent, said dispersing agent comprising a reaction product of polyisobutylene with maleic acid and/or anhydride further reacted with an amino ether/alcohol to form at least one of ester, amide and salt linkages between the amino ether/alcohol and said reaction product of maleic acid and/or anhydride thereof with polyisobutylene;
b) jetting said mixed metal oxide dispersed in said continuous medium using said dispersing agent onto said substrate to form a pigmented digital image, wherein said pigmented digital image on said substrate develops into a colored image upon firing said ceramic substrate or heating said glass substrate to provide tempering or annealing;
c) optionally applying a glaze over said digital image; and
d) heating said ceramic article at an elevated temperature or heating said glass article to anneal or temper it, wherein said image from mixed metal oxide develops color intensity upon heating.

US Pat. No. 11,065,790

FLUORINATED COPOLYMER COMPOSITION, METHOD FOR ITS PRODUCTION, AND MOLDED PRODUCT

AGC Inc., Chiyoda-ku (JP...


1. A fluorinated copolymer composition comprising the following thermoplastic resin A and the following fluorinated elastomer B, whereinthe fluorinated elastomer B is dispersed in the thermoplastic resin A,
the number average particle diameter of the fluorinated elastomer B is from 1 to 300 ?m, and
the volume ratio of the thermoplastic resin A to the fluorinated elastomer B is from 97:3 to 55:45, and
having a flexural modulus of from 1,000 to 3,700 Mpa,
wherein the thermoplastic resin A is at least one type of melt-moldable thermoplastic heat-resistant resin selected from the group consisting of a polyarylate, a polyether sulfone, a polyaryl sulfone, an aromatic polyamide, an aromatic polyether amide, an aromatic polyether imide, a polyphenylene sulfide, a polyaryl ether ketone, a polyamideimide and a liquid crystal polyester,
wherein the fluorinated elastomer B is at least one type of fluorinated elastic copolymer selected from the group consisting of a copolymer having units based on tetrafluoroethylene and units based on propylene, a copolymer having units based on hexafluoropropylene and units based on vinylidene fluoride, and a copolymer having units based on tetrafluoroethylene and units based on a perfluoro(alkyl vinyl ether), and the perfluoro(alkyl vinyl ether) is a compound represented by the following formula (I),CF2?CF(ORF)??(I)

wherein RF is a C1-8 linear or branched perfluoroalkyl group and wherein the fluorinated elastomer B has a Mooney viscosity (ML1+10, 121° C.) of from 20 to 200.

US Pat. No. 11,065,273

TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE (AD)

AFFIRIS AG, Vienna (AT)


1. A method for reducing the severity of a dementia associated with ?-amyloid deposition comprising administering to a subject in need thereof a composition comprising an effective amount of at least one aluminium salt as the sole active ingredient in a dose form of an amount exceeding an amount prescribed in the US general biological products standards of 21 C.F.R. 610.15, as of Apr. 2013.
US Pat. No. 11,065,274

PREVENTION AND TREATMENT FOR MICROBIAL INFECTIONS

University of Rochester, ...


1. A composition comprising zinc pyrithione and silver sulfadiazine wherein the weight ratio between zinc pyrithione and silver sulfadiazine is from 1:4 to 1:2, wherein the total concentration of silver sulfadiazine is 1 wt. %, and wherein the total concentration of zinc pyrithione is from 0.25 wt. % to 0.5 wt. %.
US Pat. No. 11,065,275

CROSS-LINKING AGENTS AND ASSOCIATED METHODS

University of Utah Resear...


1. A method of treating keratoconus, comprising:administering to an eye of a subject in need thereof a therapeutically effective amount of a composition comprising an active agent selected from: copper sulfate, copper carbonate, copper acetate, copper chloride, copper gluconate, copper bromide, copper fluoride, copper nitrate, copper iodide, copper perchlorate, copper molybdate, copper thiocyanate, copper tartrate, copper tetrafluoroborates, copper selenide, copper pyrophosphate, GHK-copper, copper-histidine, copper-glycinate, and combinations thereof,
wherein the composition comprises from about 0.001 wt % to about 0.1 wt % of the active agent.

US Pat. No. 11,066,569

PAINT COMPOSITION FOR TOPCOATS HAVING AN ACRYLIC RESIN AND A MELAMINE RESIN AS THE MAIN RESINS


1. A topcoat paint composition having an acrylic resin (A) and a melamine resin (B) as the main resins, which can be wet-on-wet applied onto a colored basecoat, wherein:said acrylic resin (A), relative to 100 parts by mass of said acrylic resin (A), contains 30-40 parts by mass of 2-hydroxyethyl methacrylate, 10-30 parts by mass of styrene and 25 parts by mass or more of 2-ethylhexyl acrylate,
said acrylic resin (A) does not contain, relative to 100 parts by mass of said acrylic resin (A), more than 5 parts by mass of other monomer units comprising caprolactone compound(s) and/or hydroxy group-containing (meth)-acrylates constituted of 7 or more carbons,
said acrylic resin (A) has a mass average molecular mass of 5,000-12,000, and a glass transition temperature of ?25 to ?5° C.,
the content of acrylic resin (A), relative to 100 parts by mass of total resin solids of the topcoat paint composition, is 45 or more parts by mass,
said melamine resin (B) does not contain complete alkyl ether type melamine resin, and
the content of melamine resin (B), relative to said acrylic resin (A), as resin solids mass ratio, is acrylic resin (A)/melamine resin (B)=50/50 to 80/20.

US Pat. No. 11,065,276

MUTANT BORDETELLA STRAINS AND METHODS OF USE


1. A composition comprising a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria, wherein the live attenuated pertactin-deficient Bordetella bacteria are the BPZE1P strain of Bordetella pertussis deposited with the Collection Nationale de Cultures de Microorganismes under accession number CNCM-I-5150.
US Pat. No. 11,066,570

AQUEOUS STAIN RESISTANT COATING COMPOSITION


1. An aqueous stain resistant coating composition, comprising, one or more aqueous dispersions of self-crosslinkable polymeric particles; and one or more particulate solids,wherein the polymeric particles have a Tg of 10° C. or less; and
wherein the particulate solids comprise a combination of sheet-like particulate solids and sphere-like particulate solids in a weight ratio of 1:1 or more, wherein the size of the sphere-like particulate solids is smaller than that of the sheet-like particulate solids; and
wherein the coating composition has a pigment volume concentration of 45% or more; and the coating composition is substantially free of volatile organic compounds.

US Pat. No. 11,065,277

METHOD OF AMELIORATING SIDE EFFECTS OF SICKLE CELL DISEASE TREATMENTS

Albert Einstein College o...


1. A method of reducing cell sickling and preventing a cerebral tissue pathology in a subject having a sickle cell disease with vaso-occlusion comprising:administering a 10% top-load of a pegylated hemoglobin (PEG-Hb) molecule having a higher oxygen affinity than hemoglobin in red blood cells to the subject, wherein the PEG-Hb molecule reduces cell sickling and is sufficient to protect against a cerebral tissue pathology caused by a reduced cerebral blood flow (CBF) that results from administering the 10% top-load to treat the sickle cell disease with vaso-occlusion in the subject; and
administering an amount of 5-hydroxyl methyl furfural or a composition comprising red blood cells ex vivo treated with 5-hydroxyl methyl furfural to the subject.

US Pat. No. 11,066,313

METHODS FOR REMOVING ANIONS FROM WATER

CHEMTREAT, INC., Glen Al...


1. A method of treating water that contains a target anion, the method comprising:providing a treatment composition solution containing a metal treatment agent;
increasing the pH of the treatment composition solution with a pH adjusting agent to a first pH that is greater than 8.3, and then decreasing the pH of the treatment composition solution to a second pH that is less than 4.5; and
contacting the treatment composition solution with the water that contains the target anion such that the target anion precipitates.

US Pat. No. 11,065,278

METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY

Fred Hutchinson Cancer Re...


1. An adoptive cellular immunotherapy composition comprising chimeric antigen receptor-modified CD4+ T lymphocytes and chimeric antigen receptor-modified CD8+ T lymphocytes, wherein:(a) the chimeric antigen receptor-modified CD4+ T lymphocytes in the composition consist of helper T lymphocytes that contain a chimeric antigen receptor that specifically binds to an antigen, wherein the CD4+ helper T lymphocytes are derived from: (i) a CD45RA+ CD62L+ naïve T cell enriched CD4+ population; or (ii) a CD45RA+ CD62L+ naïve T cell enriched and CD45RO+ CD62L+ central memory T cell enriched CD4+ population;
(b) the chimeric antigen receptor-modified CD8+ T lymphocytes in the composition consist of CD8+ cytotoxic T lymphocytes that are derived from a central memory-enriched CD8+ cell population and contain a chimeric antigen receptor that specifically binds to the antigen; and
wherein (a) at least 60% of the chimeric antigen receptor-modified CD4+ T lymphocytes are surface positive for CD62L and CD45RA or CD45RO; or (b) at least 80% of the chimeric antigen receptor-modified CD4+ T lymphocytes are surface positive for CD62L and CD45RA or CD45RO.

US Pat. No. 11,066,572

METHOD OF PREPARING HIGH-PERFORMANCE WATER-SOLUBLE ACRYLIC RESIN WITH HIGH SOLID CONTENT AND LOW VISCOSITY

Institute of Applied Chem...


1. A method of preparing a water-soluble acrylic resin, comprising:1) adding a mixed green solvent to a reactor and heating the reactor to 80-122° C.;
2) dispersing 7-12 parts by weight of acrylic acid, 10-25 parts by weight of an acrylate, 10-20 parts by weight of styrene, 10-30 parts by weight of a methacrylate, 2-10 parts by weight of a versatate, 26-35 parts by weight of a hydroxyl-containing methacrylate, a chain transfer agent and 90% of an initiator uniformly to produce a dispersed system and dropwise adding the dispersed system to the reactor, wherein the dropwise addition lasts for 3.5-5 h; and after the dropwise addition is completed keeping the temperature at 80-122° C. for 15-30 min;
3) adding a silicone functional monomer and a solvent to the reactor; and keeping the temperature at 80-122° C. for 0.5-1 h;
4) dropwise adding the remaining 10% of the initiator and a solvent to the reactor to obtain a reaction mixture, wherein the dropwise addition lasts for 10-30 min; and after the dropwise addition is completed, keeping the temperature at 80-122° C. for 0.5-1 h; and
5) cooling the reactor to 60° C.; and adjusting the reaction mixture to a neutralization degree of 50-80% with 4.4-12 parts by weight of an amine neutralizer followed by discharging and filtration to produce the water-soluble acrylic resin;
wherein the mixed green solvent is two solvents selected from ethanol, n-butanol, isopropanol, ethylene glycol butyl ether, propylene glycol methyl ether and propylene glycol monomethyl ether acetate;
the solvent in step (3) is isopropanol;
the solvent in step (4) is one or more of ethanol, ethyl acetate, butyl acetate and isopropanol; and
the reaction mixture comprises 1-6 parts by weight of the silicone functional monomer, 0.75-2.25 parts by weight of the chain transfer agent, and 1.8-6.7 parts by weight of the initiator.

US Pat. No. 11,065,279

PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

IMMATICS BIOTECHNOLOGIES ...


1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that are capable of killing cancer cells that present a peptide consisting of the amino acid sequence of GLLTQVHIL (SEQ ID NO: 51),wherein said cancer is selected from the group consisting of acute myeloid leukemia, breast cancer, colorectal cancer, glioblastoma, hepatocellular carcinoma, non-small cell lung cancer, pancreatic cancer, and urinary bladder carcinoma.

US Pat. No. 11,065,280

HEPATOCYTES WITH HIGH REGENERATIVE CAPACITY FOR LIVER REPAIR

The Regents of the Univer...


1. A method for purifying a hybrid hepatocyte (HybHP) cell from a normal mammalian liver, said method comprising,a) preparing a single-cell suspension from said normal mammalian liver,
b) combining said single-cell suspension withi) at least one first antibody that specifically binds to a plasma membrane first protein marker of liver ductal (DC) cells, and
ii) at least one second antibody that specifically binds to a second protein marker of conventional hepatocyte (cHP) cells, wherein said second protein marker of cHP cells is underexpressed in said HybHP cells compared to cHP cells,

wherein said combining is under conditions for specific binding of said at least one first antibody to said first protein marker, and of said at least one second antibody to said second protein marker, and wherein said specific binding produces a first composition that comprises a first antibody-HybHP cell-second antibody conjugate, and
c) isolating said first antibody-HybHP cell-second antibody conjugate from said single-cell suspension, thereby producing a second composition that comprises a purified HybHP cell.

US Pat. No. 11,066,316

TREATMENT OF OIL AND GREASE IN WATER USING ALGAE

The University of Akron, ...


1. A method for treating an industrial wastewater medium, the method comprising steps of:providing a wastewater stream including industrial wastewater and at least one of oil or grease, the at least one of oil or grease being in the form of droplets having an initial droplet size, wherein at least a portion of the at least one of oil or grease is insoluble in the industrial wastewater,
combining phagotrophic algae with the wastewater stream to form a combined medium, wherein the combined medium has a maximum cell number concentration of the phagotrophic algae of 2.89×107 algae cells/mL of the combined medium, wherein the phagotrophic algae are selected from the group consisting of Dinobryon, Chrysophaerella, Uroglena, Catenochrysis, Chromulina, and Chrysococcus,
mechanically agitating or mechanically mixing the combined medium to thereby form the droplets into a smaller droplet size smaller than the initial droplet size, and
allowing the algae to engulf at least a portion of the insoluble portion in the combined medium, wherein the wastewater stream has an oil concentration of 12.8 g/L or more prior to the step of combining and the combined medium has an oil concentration of 5.9 g/L or less after the step of allowing.

US Pat. No. 11,065,281

COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC ENTERITIS CONTAINING DNA FRAGMENT MIXTURE ISOLATED FROM SPERM OR TESTIS OF FISH

PharmaResearch Co., Ltd.,...


1. A method for treating ischemic colitis in a subject, comprising administering to the subject a therapeutically effective amount of a mixture of DNA fragments isolated from sperm or testis of fish, wherein the mixture of DNA fragments has a molecular weight of 50-1,500 kDa.
US Pat. No. 11,066,318

GREEN GLASS COMPOSITION

KCC Glass Corporation, S...


1. A method for preparing a green glass composition, the method comprising:constituting a glass raw material batch such that a weight ratio of Glauber salt to a reducing agent in the glass raw material batch becomes 10 to 60,
wherein the green glass composition comprises 65-75 wt % of SiO2, 0.3-3.0 wt % of Al2O3, 10-18 wt % of Na2O+K2O, 5-15 wt % of CaO, 1-7 wt % of MgO, 0.65-1.3 wt % of Fe2O3, 0.1-0.4 wt % of TiO2, and 0.05-0.20 wt % of SO3, based on 100 wt % of a soda lime mother glass composition,
wherein an oxidation-reduction ratio of Fe2O3 is 0.22 to 0.38, and
wherein each one of Cr, Ce and Co components has an amount of less than 0.001 wt % based on 100 wt % of the soda lime mother glass composition.

US Pat. No. 11,065,283

IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF


1. A method of treating an inflammatory disease, disorder or condition in an individual, the method comprising administering to the individual an effective amount of an immunomodulatory composition, the immunomodulatory composition comprising:a) live Caulobacter spp.; and
b) a pharmaceutically acceptable excipient;

wherein the composition is administered via an oral, nasal, or topical route of administration;wherein the Caulobacter spp. is selected from the group consisting of Caulobacter crescentus, lipopolysaccharide-negative Caulobacter crescentus, S-layer-negative Caulobacter crescentus, Caulobacter vibroides, Caulobacter subvibriodes, Caulobacter henricii, Caulobacter fusiformis, and Caulobacter intermedius.

US Pat. No. 11,066,577

ELECTRICALLY CONDUCTIVE ADHESIVE FILM AND DICING-DIE BONDING FILM USING THE SAME

FURUKAWA ELECTRIC CO., LT...


1. An electrically conductive adhesive film comprising:a metal particle (P); and
a resin (M),
wherein the resin (M) comprises a thermosetting resin (M1),
the metal particle (P) has an average particle size (d50) of 20 ?m or less, and
the metal particle (P) comprises 10% by mass or more of a first metal particle (P1) having a fractal dimension of 1.1 or more when viewed in a projection drawing in a primary particle state, wherein a loss tangent (tan ?) defined by a ratio of a loss elastic modulus to a storage elastic modulus at 60° C. and 1 Hz in a B-stage state is 1.4 or higher.

US Pat. No. 11,065,284

COMPOSITIONS FOR FECAL FLORAL TRANSPLANTATION AND METHODS FOR MAKING AND USING THEM AND DEVICES FOR DELIVERING THEM

Finch Therapeutics Holdin...


1. An acid-resistant capsule comprising a saline suspension of a selected fraction of a fecal flora derived from a stool of a healthy human donor, wherein the fraction comprises uncultured bacteria from the phylum Firmicutes,wherein the fraction is separate from rough particulate matter of the stool, and wherein the proportion of Firmicutes bacteria relative to non-Firmicutes bacteria in the fraction is greater than such proportion in the fecal flora.

US Pat. No. 11,066,578

PRESSURE SENSITIVE ADHESIVE COMPOSITIONS


1. A pressure sensitive adhesive composition comprising:(a) 50 wt % to 75 wt % based on the total weight of the composition of an acrylic emulsion;
(b) less than 10 wt % based on the total weight of the composition of non-halogenated flame retardants comprising: melamine cyanurate and ammonium polyphosphate; and
(c) halogenated flame retardants comprising at least one brominated organic compound;
wherein the total amount of melamine cyanurate is from 0.5 wt % to 2.5 wt % based on the total weight of the composition;
the total amount of ammonium polyphosphate is from 4 wt % to 9 wt % based on the total weight of the composition;
the total amount of brominated organic compound is at least 14.5 wt % based on the total weight of the composition; and
the total amount of non-halogenated flame retardants and halogenated flamed retardants is less than 30 wt % based on the total weight of the composition.

US Pat. No. 11,065,285

BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION

DNATRIX, INC., Houston, ...


1. A method for treating a brain tumor in a patient having or suspected of having a primary or metastatic brain tumor comprising administering to said patient (a) an oncolytic virus selected from the group consisting of Delta-24 and Delta-24 RGD; and (b) a PD-1/PD-L1 receptor antagonist.
US Pat. No. 11,066,579

CURABLE COMPOSITION AND METHOD FOR REINFORCING SHAPED STRUCTURE WITH USE OF SAME

TOAGOSEI CO., LTD., Toky...


1. A curable composition consisting essentially ofas a polymerizable monomer, a 2-cyanoacrylic acid ester; and
a surface conditioner,

in which the surface conditioner is contained in an amount of 0.001-10 parts by mass relative to 100 parts by mass of the 2-cyanoacrylic acid ester and the composition has a surface tension of 28 mN/m or less at 25° C.
US Pat. No. 11,065,286

HIGH MOBILITY GROUP BOX I MUTANT


1. An oncolytic vaccinia virus comprising an exogenous nucleic acid that codes for a variant High Mobility Group Box 1 (HMGB1) comprising a sequence that comprises a mutation in one or a combination of the following amino acid positions of SEQ ID NO: 16 (wild-type HMGB1): 35, 42, 89, 181, 189, and 202.
US Pat. No. 11,066,580

PRESSURE-SENSITIVE ADHESIVE COMPOSITION FOR FOLDABLE DISPLAY

INNOX ADVANCED MATERIALS ...


1. A pressure-sensitive adhesive composition for a foldable display, the pressure-sensitive adhesive composition comprising an acrylic polymer and a crosslinking agent and satisfying the following conditions (1) to (3):60×104 Pa?A?95×104 Pa??(1)
8×104 Pa?B?11×104 Pa??(2)
2×104 Pa?C?5×104 Pa??(3)
wherein, in the condition (1), A is a storage modulus of the pressure-sensitive adhesive composition after curing as measured at a temperature of ?20° C., an angular frequency of 6.28 rad/s, and a strain of 1%,
in the condition (2), B is a storage modulus of the pressure-sensitive adhesive composition after curing as measured at a temperature of 25° C., an angular frequency of 6.28 rad/s, and a strain of 1%, and
in the condition (3), C is a storage modulus of the pressure-sensitive adhesive composition after curing as measured at a temperature of 200° C., an angular frequency of 6.28 rad/s, and a strain of 1%.

US Pat. No. 11,065,287

METHODS OF MODULATING IMMUNE AND INFLAMMATORY RESPONSES VIA ADMINISTRATION OF AN ALGAL BIOMASS

ZIVO BIOSCIENCE, INC., K...


1. A method of modulating inflammation and/or modulating an immune response in a bovine animal relating to bovine mastitis or bovine respiratory disease complex, said method comprising administering to the bovine animal in need thereof a therapeutically effective amount of a composition comprising an algal biomass or a supernatant obtained by processing the biological material of NCMA Deposit # PATENT201602001.
US Pat. No. 11,066,581

PRESSURE-SENSITIVE ADHESIVE COMPOSITION FOR FOLDABLE DISPLAY

INNOX ADVANCED MATERIALS ...


1. A pressure-sensitive adhesive composition for a foldable display, the pressure-sensitive adhesive composition comprising an acrylic polymer and a crosslinking agent and satisfying the following Relational Formulas 1 and 2:0?X?100??[Relational Formula 1]
Y1=?1×X??1??[Relational Formula 2]
wherein, in Relational Formulas 1 and 2, X represents sweep frequency (Hz), Y1 represents a storage modulus (Pa) of the pressure-sensitive adhesive composition after curing as measured at a temperature of ?20° C. and a strain of 1%, ?1 is 15×104 to 45×104, and ?1 is 40×104 to 90×104.

US Pat. No. 11,065,288

NEURON ACTIVATOR

KINJIRUSHI CO., LTD., Na...


1. A neuron activator that activates neurons,the neuron activator including an effective amount of a mixture of(a) 6-methylsulfinylhexyl isothiocyanates or glycosides thereof, and
(b) docosahexaenoic acid to activate neurons, and

wherein a molar ratio of (b) docosahexanoic acid to (a) 6-methylsulfinylhexyl isothiocyanates or glycosides thereof ((b)/(a)) is 0.2 or more and 80 or less.

US Pat. No. 11,066,324

LITHIUM CONTAINING GLASSES

CORNING INCORPORATED, Co...


1. A glass article comprising, on an oxide basis:from greater than or equal to 65 mol% to less than or equal to 74 mol% SiO2;
from greater than or equal to 7 mol% to less than or equal to 12 mol% Al2O3;
from greater than or equal to 5 mol% to less than or equal to 16 mol% B2O3;
from greater than or equal to 0 mol% to less than or equal to 4 mol% Na2O;
from greater than or equal to 0 mol% to less than or equal to 5 mol% P2O5;
from greater than or equal to 5 mol% to less than or equal to 11 mol% Li2O; and
from greater than or equal to 0.5 mol% to less than or equal to 6.5 mol% divalent cation oxides, wherein a molar ratio of Al2O3:(R2O+RO) is greater than or equal to 0.9, where R20 is a sum of alkali metal oxides in mol% and RO is a sum of divalent cation oxides in mol%.

US Pat. No. 11,065,289

SUBSTANCE AND METHOD FOR THE TREATMENT OF POXVIRUS


1. A process for creating a substance for the treatment of poxvirus molluscum infection, comprising:a) collecting Anacardium occidentale seeds;
b) grinding said Anacardium occidentale seeds and mixing said Anacardium occidentale seeds into a predetermined amount of sunflower oil to form a mixture;
c) heating said mixture and then lowering the heating temperature of said mixture once the mixture ceases to produce smoke thereby forming a substance; and
d) straining said substance to remove seed particles.

US Pat. No. 11,066,325

ALKALI-FREE GLASS

AGC Inc., Chiyoda-ku (JP...


1. An alkali-free glass, which comprises, as represented by mol % based on oxides,SiO2 65.5 to 70%,
Al2O3 11 to 14%,
B2O3 3 to 5.5%,
MgO 7 to 10%,
CaO 3 to 9%,
SrO 1 to 5% and
BaO 0 to 1%,
wherein
the mol % content of the alkaline earth metals is related according to [MgO]>[CaO]>[SrO]>[BaO],
[SiO2]+0.7[Al2O3]+1.2[B2O3]+0.5[MgO]0.4[CaO]?0.25[SrO]?0.88[BaO]is at least 85,
[SiO2]+0.45[Al2O3]+0.21[B2O3]?0.042[MgO]+0.042[CaO]+0.15[SrO]+0.38[BaO] is from 72 to 75,
0.4[SiO2]0.4[Al2O3]0.25[B2O3]?0.7[MgO]?0.88[CaO]?1.4[SrO]?1.7[BaO]is at most 19,
the specific modulus is at least 32 MN·m/kg,
the strain point is from 690 to 710° C.,
the density is at most 2.54 g/cm3,
the average thermal expansion coefficient at from 50 to 350° C. is at least 35×10?7/° C., and
the temperature T2 at which the glass viscosity reaches 102 dPa·s is from 1,610 to 1,680° C.

US Pat. No. 11,066,583

ADMIXED MODIFIERS FOR ADHESIVES

The United States of Amer...


2. The improved adhesive according to claim 1, wherein the first monomer is a dopamine monomer, a maleimide-dopamine monomer, or a derivative thereof.
US Pat. No. 11,065,290

TOPICAL COMPOSITION

BIOPHARM NZ LIMITED, Ham...


1. A therapeutic topical composition, comprising a therapeutically effective amount of an extract of Galenia africana, wherein the extract has anti-microbial and anti-oxidant activity, and wherein the composition further comprises a therapeutically effective amount of rooibos and/or an extract from rooibos tea plant.
US Pat. No. 11,066,326

GLASS

NIPPON ELECTRIC GLASS CO....


1. A glass, comprising as a glass composition, in terms of mass %, 55% to 70% of SiO2, 18% to 25% of Al2O3, 1% to 5% of B2O3, 0% to 0.5% of Li2O+Na2O+K2O, 0% to 4% of MgO, 3% to 11% of CaO, 0% to 4% of SrO, 0% to 11% of BaO, 0.001% to 1% of SnO2, and 0% to 1.5% of P2O5, and having a ratio of SiO2/Al2O3 in terms of mass % of from 2.5 to 3.1 and a strain point of more than 715° C.
US Pat. No. 11,066,584

LOW DENSITY AEROSPACE COMPOSITIONS AND SEALANTS

PRC-DeSoto International,...


1. A composition comprising:(a) a thiol-terminated polythioether prepolymer having an average thiol functionality from 2.05 to 2.8, wherein the thiol-terminated polythioether prepolymer comprises the chemical structure of Formula (1):—R1[—S—(CH2)2—O—[—R2—O—]m—(CH2)2—S—R1]n—??(1)

wherein,each R1 is independently selected from a C2-10 n-alkanediyl group, a C3-6 branched alkanediyl group, a C6-8 cycloalkanediyl group, a C6-10 alkanecycloalkanediyl group, a heterocyclic group, and a —[(—CHR3—)p—X—]q—(CHR3)r— group, wherein each R3 is independently selected from hydrogen and methyl;
each R2 is independently selected from a C2-10 n-alkanediyl group, a C3-6 branched alkanediyl group, a C6-8 cycloalkanediyl group, a C6-14 alkanecycloalkanediyl group, a heterocyclic group, and a —[(—CH2—)p—X—]q—(CH2)r— group;
each X is independently selected from O, S, and —NR—, wherein R is selected from hydrogen and methyl;
m ranges from 0 to 50;
n is an integer ranging from 1 to 60;
p is an integer ranging from 2 to 6;
q is an integer ranging from 1 to 5; and
r is an integer ranging from 2 to 10;

(b) a curing agent comprising groups reactive with thiol groups; and
(c) from 35 vol % to 55 vol % of coated low-density thermoplastic microcapsules, wherein,the coated low-density thermoplastic microcapsules comprise a coating of an aminoplast resin;
the coated low-density thermoplastic microcapsules are characterized by a specific gravity less than 0.1;
vol % is based on the total volume of the composition; and

the composition is characterized by a specific gravity less than 0.9, wherein the specific gravity is determined according to ASTM D1475 (modified).

US Pat. No. 11,065,291

TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING TUMOURS, PREPARATION METHOD THEREFOR AND USE THEREOF

Angang Zuo, Beijing (CN)...


1. A medicinal composition for treating tumors, wherein the medicinal composition is prepared by raw materials with weight percentage as follows:Sophora flavescens 3%-12%, wild Chrysanthemum flower 5%-15%, honeysuckle 2%-12%, mint 5%-15%, Poria cocos 5%-15%, Atractylodes lancea 10%-20%, cinnamon 0.5%-3%, clove 0.5%-3%, Astragalus 3%-12%, Ganoderma lucidum 5%-15%, Ligusticum striatum 10%-20%, Aucklandia root 5%-12%, and Radix glycyrrhizae 2%-10%;
wherein a dosage form of the medicinal composition is a pill, a capsule, a tablet, a gel, or a film.

US Pat. No. 11,066,585

ORGANOPOLYSILOXANE COMPOSITION AND METHOD FOR PRODUCING SAME, AND SILICONE COMPOSITION FOR MIST SUPPRESSOR AS WELL AS SOLVENT-FREE RELEASE PAPER OR RELEASE FILM

SHIN-ETSU CHEMICAL CO., L...


1. A method for preparing an organopolysiloxane composition comprising the steps of: effecting addition reaction of an organopolysiloxane of structure having the formula (1) and an organohydrogenpolysiloxane of structure having the formula (2) in a solvent in the presence of a platinum group metal base compound, the amount of the solvent being 10 to 50 times the total weight of the polysiloxanes of formulae (1) and (2), to form a product, adding the organopolysiloxane of structure having the formula (1) and the organohydrogenpolysiloxane of structure having the formula (2) again to the product, effecting addition reaction in the presence of the platinum group metal base compound, repeating at least one time the addition and reaction steps, thereby yielding an organopolysiloxane crosslinked product,M?MVi?D?DVi?T?TVi?Q???(1)
M?MHlD?DH?T?TH?Q???(1)

wherein M is R3SiO1/2, MVi is R2PsiO1/2, D is R2SiO2/2, DVi is RPSiO2/2, T is RSiO3/2, TVi is PSiO3/2, MH is R2HSiO1/2, DH is RHSiO2/2, TH is HSiO3/2, Q is SiO4/2, R is each independently a substituted or unsubstituted C1-C12 monovalent hydrocarbon group free of aliphatic unsaturation, P is an alkenyl group: —(CH2)a—CH?CH2 wherein a is 0 or an integer of 1 to 6, ?, ?, ?, ?, ?, ?, ?, ?, l, ?, ?, ?, and ? are each independently 0 or a positive number, ?, ? and ? are not equal to 0 at the same time, ?+?+??2, l, ?, and ? are not equal to 0 at the same time, l+?+??2, ?+?+? and l+?+? are not equal to 2 at the same time.
US Pat. No. 11,065,292

FEIJOA FRUIT EXTRACT

CALLAGHAN INNOVATION, Lo...


1. A method for reducing obesity in a patient in need thereof, comprising administering to the patient an effective amount of feijoa fruit extract, thereby reducing obesity in the patient, wherein the patient is a human patient with Type-2 diabetes and/or hyperglycemia.
US Pat. No. 11,065,293

PHARMACEUTICAL COMPOSITION FOR DECREASING THE SIDE EFFECTS OF CANCER DRUG, AND MANUFACTURING METHOD AND USES THEREOF


1. A method for decreasing side effects of a cancer drug in a patient in need thereof, comprising:administering an effective amount of a pharmaceutical composition to the patient,
wherein the pharmaceutical composition comprises:
a mushroom component consisting of 24-36 grams of Phellinus linteus, 16-24 grams of Ganoderma lucidum, 16-24 grams of Agaricus subrufescen, 4-6 grams of Antrodia cinnamomea, 4-6 grams of Caterpillar fungus;
a rhizome component consisting of 16-24 grams of Rhizoma polygonati, 8-12 grams of Astragalus, 8-12 grams of Salvia miltiorrhiza, 8-12 grams of Codonopsis pilosula, 12-18 grams of Hedyotis diffusa, 12-18 grams of Eucommia ulmoides, 8-12 grams of Atractylodes macrocephala, 8-12 grams of Radix trichosanthis, 8-12 grams of Eleutherococcus senticosus, 8-12 grams of Ophiopogon japonicas, 8-12 grams of Rhodiola, 2.4-3.6 grams of Peeled Licorice;
a fruit component consisting of 12-18 grams of Job's Tears, 8-12 grams of Ligustrum lucidum, 8-12 grams of Schisandra chinensis, 9.6-14.4 grams of Germinated brown rice, 8-12 grams of lotus seed, 8-12 grams of Black sesame, 8-12 grams of Corn Silk, 8-12 grams of Siraitiagros venorii, 1.6-2.4 grams of powder extract from red grape skin;
a leaf component consisting of 8-12 grams of spinach, 8-12 grams of germinated Broccoli, 8-12 grams of papaya leaf, 6.4-9.6 grams of lotus leaf;
a flower consists component consisting of 8-12 grams of Chrysanthemum, 8-12 grams of Cota tinctoria, 8-12 grams of Lonicera Japonica, 8-12 grams of Matricaria recutita (Chamomile);
an alga component consisting of 8-12 grams of seaweed, 8-12 grams of sea-tangle, 8-12 grams of kelp;
an energy-rich liquid consisting of 4.5 to 5.5 mg of ferric chloride and 200 ml of distilled water;
a salt-rich liquid consisting of 112.5-137.5 grams of deep sea salt, 27-33 grams of magnesium chloride, 18-22 ml of brine, 0.99-1.21 grams of calcium chloride and 0.495-0.605 grams potassium chloride;
an assist agent consisting of 18-22 grams of citric acid, 18-22 grams of selenium yeast, 270-330 mg of coenzyme Q10 and 2.7-3.3 grams of vitamin C;
an anti-oxide agent consisting of 9-11 grams of chitin oligosaccharides, 4.5-5.5 grams of glutathione, 0.9-1.1 grams of pine bark, and 0.9 -1.1 grams of Fucoidan,
wherein the pharmaceutical composition can protect an organ from the side effects of the cancer drug, increase immunity, reduce pain, or improve the efficacy of the cancer drug, and
wherein the cancer drug is selected form the group consisting of 5-fluorouracil (5-FU), Taxol, cisplatin, anthracycline, cyclophosphamide and a combination thereof.

US Pat. No. 11,066,329

ANTIREFLECTIVE GLASS SUBSTRATE AND METHOD FOR MANUFACTURING THE SAME

AGC GLASS EUROPE, Louvai...


1. A method for producing an antireflective glass substrate comprising:a) providing a source gas selected from O2 and/or N2,
b) ionizing the source gas so as to form a mixture of single charge ions and multicharge ions of O and/or N,
c) accelerating the mixture of single charge ions and multicharge ions of O and/or N with an acceleration voltage so as to form a beam of single charge ions and multicharge ions of O and/or N wherein an acceleration voltage A is between 13 kV and 40 kV and an ion dosage D is between 5.56×1014×A/kV+4.78×1016 ions/cm2 and ?2.22×1016×A/kV+1.09×1018 ions/cm2,
d) providing a glass substrate,
e) positioning the glass substrate in a trajectory of the beam of single charge and multicharge ions of O and/or N, and
f) implanting the single charge and multicharge ions of O and/or N such that a concentration of implanted O and/or N is below 2 atomic % throughout an implanted depth in the glass substrate.

US Pat. No. 11,065,294

COMPOSITION INCLUDING ORIENTAL MEDICINE TO TREAT NEOPLASTIC DISEASE

COMPREHENSIVE AND INTEGRA...


1. A method of treating an individual having cancer comprising administering effective amounts of an anticancer agent and a medicine to said individual, wherein:the cancer is chosen from breast cancer, liver cancer, and renal cancer;
the only anticancer agent is tamoxifen, gefitinib or sorafenib; and
the medicine is jaeumganghwa-tang, bojungikgi-tang, a bojungikgi-tang extract, or a yukmijihwang-tang extract.

US Pat. No. 11,066,330

COPOLYMERS HAVING A GRADIENT STRUCTURE

SIKA TECHNOLOGY AG, Baar...


1. A copolymer having a polymer backbone and side chains bonded thereto, and comprising at least one ionizable monomer unit M1 and at least one side chain-bearing monomer unit M2, the copolymer having:at least one section A having a gradient structure in a direction along the polymer backbone with regard to the ionizable monomer unit M1 and/or with regard to the side chain-bearing monomer unit M2, and
at least one section B having an essentially constant local concentration of monomers and/or a random distribution of monomers, wherein the at least one section B comprises ionizable monomer units M1 and/or side chain-bearing monomer units M2,
wherein a ratio of the number of monomer units in the at least one section A to the number of monomer units in the at least one section B is in the range of 80:20 to 20:80.

US Pat. No. 11,065,295

COMPOSITIONS AND METHODS FOR NUTRITIONAL SUPPLEMENTS

DAILYCOLORS HEALTH INC., ...


1. A nutritional composition, comprising:a nutritionally acceptable carrier in combination with a plurality of chemically distinct polyphenol-containing plant materials having a red color, a green color, an orange-yellow color, and a purple-blue color;wherein the red colored plant materials comprise an apple extract, a pomegranate extract, a tomato powder, and a beet root powder;
wherein the green colored plant materials comprise an olive extract, a rosemary extract, a green coffee bean extract, and a kale powder;
wherein the orange-yellow colored plant materials comprise an onion extract, a ginger extract, a grapefruit extract, and a carrot powder;
wherein the purple-blue colored plant materials comprise a grape extract, a blueberry extract, a currant powder, and an elderberry powder; and

wherein the combination of plant materials is a synergistic combination with respect to inhibition of at least one biochemical marker selected from the group consisting of BACE1, CD38, CD73, CDK5, JAK1, JAK2, and JAK3.

US Pat. No. 11,066,589

USE OF BIODEGRADABLE HYDROCARBON FLUIDS AS DRILLING FLUIDS

TOTAL MARKETING SERVICES,...


1. Drilling fluid comprising:a fluid having an initial boiling point and a final boiling point in the range of from 200° C. to 400° C. and a boiling range below 80° C., said fluid comprising more than 95% isoparaffins and less than 3% naphthenes by weight, a biocarbon content of at least 95% by weight, containing less than 100 ppm aromatics by weight, and
barite

wherein the fluid consists of a mixture of two fractions, each fraction having an initial boiling point and a final boiling point in the range 220° C.-340° C., and a boiling range of less than 80° C.,
where at least one fraction has an initial boiling point higher than 250° C.,
where at least one fraction has an initial boiling point lower than 250° C.
US Pat. No. 11,069,936

ELECTRIC WORK VEHICLE

Kubota Corporation, Osak...


1. An electric work vehicle comprising:a traveling vehicle body;
a battery container provided in the traveling vehicle body;
a battery pack that is removably attached to the battery container, the battery pack comprising a plurality of battery modules therein;
a guiding unit provided in the battery container, the guiding unit being configured to guide the battery pack between a loading/unloading position at which the battery pack is loaded onto and unloaded from the battery container and a containing position at which the battery pack is contained; and
a guided unit provided in the battery pack, the guided unit being guided by the guiding unit,
wherein a pair of rollers are provided in one of the guiding unit and the guided unit,
a pair of engaging portions to be engaged with the rollers are provided in the other of the guiding unit and the guided unit, and
when the battery pack is loaded and unloaded at the loading/unloading position, the rollers are configured to function as pivot fulcrums for enabling, by engaging with the engaging portions, the battery pack to pivot for loading and unloading relative to the battery container.

US Pat. No. 11,065,296

ANTIMICROBIAL PEPTIDE, ITS ANALOG AND USE

City University of Hong K...


1. A pharmaceutical composition for treating a bacterial infection, comprising an effective amount of a peptide and a pharmaceutically tolerable excipient, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 17.
US Pat. No. 11,065,297

METHOD AND FORMULATION FOR INHALATION

MONASH UNIVERSITY, Clayt...


1. A method for the treatment or prevention of post partum haemorrhage comprising administering to a subject in need thereof an inhalable dry powder, wherein said inhalable dry powder comprises spray dried particles comprising(a) oxytocin or carbetocin,
(b) L-leucine, the L-leucine being present in the amount from 10 to 40% by weight based on the dry weight of said spray dried particles excluding the weight of oxytocin or carbetocin, and
(c) the weight remainder of said spray dried particles being an amorphous glass matrix consisting essentially of trehalose, and the oxytocin or carbetocin being dispersed within the amorphous glass matrix, and
wherein the inhalable dry powder is prepared by a process comprising: preparing an aqueous solution or suspension comprising oxytocin or carbetocin, trehalose, and L-leucine; and spray drying the aqueous solution or suspension to produce the inhalable dry powder, and the amount of dry powder administered is sufficient to provide a dose of oxytocin or carbetocin that provides an effective and rapid onset of action for treating or preventing post partum haemorrhage, and said dose is about 200 IU.

US Pat. No. 11,065,298

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS


1. A composition for reducing symptoms of influenza, the composition comprising:humic acid or a derivative thereof; and
a peptide (CZV2.14) consisting of a sequence of Gly-Glu-Pro-Pro-Pro-Gly-Lys Pro-Ala-Lys-Asp-Ala-Gly-Lys (SEQ ID NO: 1).

US Pat. No. 11,065,299

COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE RESPONSE

Northwestern University, ...


1. A method of treating an AIM2 and 1F116 inflammasome associated inflammatory disease comprising administering a composition comprising a polypeptide having 70% or greater sequence identity with PYRIN domain-only protein 3 (POP3) (SEQ ID NO: 62).
US Pat. No. 11,066,593

MICROEMULSION FLOWBACK AIDS FOR OILFIELD USES

STEPAN COMPANY, Northfie...


1. A composition comprising an oil-in-water microemulsion produced by combining an aqueous brine with a flowback aid mixture which comprises:(a) an oil selected from the group consisting of hydrocarbons, terpenes, and C6-C30 fatty alkyl esters;
(b) a fatty alcohol ethoxylate; and
(c) a quaternized fatty amine ethoxylate;
wherein the aqueous brine comprises naturally occurring formation brine, process water, seawater, or a combination thereof;
wherein the amount of oil is within the range of 1 to 12 wt. % based on the amount of flowback aid mixture, and the microemulsion has a surface tension at 25° C. of less than 30 mN/m and a Z-average particle size as determined by dynamic light scattering at 25° C. of less than or equal to 10 nm.

US Pat. No. 11,065,300

IMMUNOMODULATOR FOR HYPERSENSITIVITY REACTION TO HOUSE DUST MITE-DERIVED ALLERGEN

MD HEALTHCARE INC., Seou...


1. A method of inducing defense immunity to at least one mite allergen, the method comprising:administering, to a subject, a composition comprising bacteria-derived extracellular vesicles loaded with at least one mite allergen in an amount sufficient to induce defense immunity to the at least one mite allergen in the subject,
wherein the bacteria-derived extracellular vesicles loaded with the at least one mite allergen comprise isolated extracellular vesicles of bacteria transformed with at least one gene configured to express the at least one mite allergen,
wherein an outer membrane of the isolated extracellular vesicles comprises endotoxin,
wherein the composition further comprises an effective amount of a drug inhibiting toxicity of the endotoxin,
wherein the composition is administered to the subject multiple times, and
wherein the multiple times comprise at least one intramuscular injection followed by at least one nasal administration.

US Pat. No. 11,065,301

PHARMACEUTICAL COMPOSITION FOR AMELIORATING THE SYMPTOMS AND DISEASE OF THE RESPIRATORY INFECTION CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), WHICH COMPRISES AT LEAST ONE AGENT THAT NEUTRALIZES THE FUNCTION OF TSLP AND/OR TSLPR AND/OR OX40L AND/OR CD177 MOLEC

PONTIFICIA UNIVERSIDAD CA...


1. Pharmaceutical composition for ameliorating the symptoms and disease of the respiratory infection caused by human Metapneumovirus (hMPV), comprising at least one agent that neutralizes the function of thymic stromal lymphopoietin (TSLP) and OX40L molecules, and a pharmaceutically acceptable excipient,wherein the agent that neutralizes the function of TSLP molecule is a monoclonal antibody comprising 3 heavy chain CDR sequences comprising SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and 3 light chain CDR sequences comprising SEQ ID NO: 4, 5 and 6, or a monoclonal antibody having 3 heavy chain CDR sequences comprising SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, and 3 light chain CDR sequences comprising SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12,
wherein the agent that neutralizes the function of OX40L molecule is a monoclonal antibody having a light chain variable domain sequence comprising SEQ ID NO: 13 and a heavy chain variable domain sequence comprising SEQ ID NO: 14.

US Pat. No. 11,066,595

BIOCIDE COMPOSITION AND USE THEREOF

JUSTEQ, LLC, Deerfield, ...


1. A process for reducing a bacterial population in a gas or oil well comprising,treating the gas or oil well with an aqueous, oxidizing biocide comprising a stabilized hypochlorous acid solution having a pH of at least 11 and a water soluble bromide ion source, wherein the aqueous, oxidizing biocide contains about 1% by weight to about 20% by weight of a chlorine source, about 1% by weight to about 20% by weight of a stabilizer, about 5% by weight to about 10% by weight of a base, about 0.1% by weight to about 15% by weight of a water soluble bromide ion source, and about 35% by weight to about 92.9% by weight of water, wherein the oil or gas well contains one or more compositions wherein the one or more compositions comprise one or more crosslinkers, gelling agents, friction reducers, or surfactants.

US Pat. No. 11,065,302

COMPOSITIONS COMPRISING FUSION VARIANTS OF FGF19 POLYPEPTIDES

NGM Biopharmaceuticals, I...


US Pat. No. 11,066,338

ANTIMICROBIAL GLAZE AND PORCELAIN ENAMEL VIA DOUBLE LAYER GLAZE WITH HIGH ZINC CONTENT

AS America, Inc., Piscat...


1. Sanitary ware comprising a multilayer antimicrobial ceramic glaze, the ceramic glaze comprisinga base glaze layer containing from 0.0 percent by weight to about 8.0 percent by weight ZnO; and
a top glaze layer containing from about 8.0 percent by weight to about 35.0 weight percent ZnO,
wherein a total ZnO content in the multilayer glaze is less than 5.0 weight percent.

US Pat. No. 11,069,427

MATHEMATICAL PROCESSES FOR DETERMINATION OF PEPTIDASE CLEAVAGE

IOGENETICS, LLC, Madison...


1. A computer implemented process of identifying peptidase cleavage sites in a polypeptide comprising:a) obtaining an amino acid sequence for a target polypeptide;
b) deriving an ensemble of peptidase cleavage prediction equations for each possible cleavage site dimer by:
(i) assembling experimentally derived data comprising a multiplicity of measurements of amino acid physicochemical properties;
(ii) producing a correlation matrix of the experimentally derived data;
(iii) deriving by Principal Component Analysis multiple uncorrelated dimensionless, weighted and ranked proxy descriptors to describe at least 80% of the variance in said physicochemical properties of individual amino acids,
(iv) using said proxy descriptors to describe individual amino acids in a set of peptides each of which comprises a specific cleavage site dimer experimentally determined to be cleaved, and to describe the individual amino acids in a set of peptides each of which comprises the same cleavage site dimer experimentally determined to be uncleaved;
(v) comparing, via probabilistic modeling, the amino acid descriptors of said peptides comprising said experimentally determined cleaved and uncleaved cleavage site dimers to derive a cleavage prediction equation for said specific cleavage site dimer based on that peptide set;
(vi) repeating the steps of (iv) and (v) multiple times, each time with a different set of peptides that comprise the same cleavage site dimer and are experimentally determined to be cleaved or not cleaved, thereby deriving an ensemble of independently derived peptidase cleavage prediction equations for said specific cleavage site dimer;
(vii) repeating the process of (iv) to (vi) to derive ensembles of independently derived prediction equations for every possible cleavage site dimer up to a total of 400 such ensembles;
(viii) storing said ensembles of independently derived prediction equations on a non-transitory computer readable medium;
(c) in-putting said amino acid sequence from said target polypeptide into a computer;
(d) applying said proxy descriptors from said Principal Component Analysis to describe individual amino acids in said target polypeptide sequence;
(e) deriving vectors to describe a plurality of peptides of defined length in said target polypeptide;
(f) via said computer processor applying said up to 400 ensembles of independently derived peptidase cleavage prediction equations to said plurality of peptides of defined length from said target polypeptide to predict a plurality of peptidase cleavage sites in said target polypeptide;
(g) identifying, by consensus of the ensembles of prediction equations, the probability of cleavage at any given cleavage site dimer in said target polypeptide;
(h) defining amino acids subsets in said target polypeptide that are predicted to be cleaved by a peptidase; and
(i) determining if the resulting amino acid subsets are predicted to have MHC binding properties and to function as a T cell epitope that generates an immune response;
(j) preparing an immunogen from amino acid subsets that are predicted to have MHC binding properties and to function as a T cell epitope that generates an immune response; and
(k) administering an effective amount of the immunogen to a subject under conditions such that an immune response is generated.

US Pat. No. 11,065,303

COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION

ACCELERON PHARMA INC., C...


1. A method of treating pulmonary arterial hypertension, comprising administering to a patient in need thereof an effective amount of a fusion protein comprising an ActRIIA polypeptide, wherein said ActRIIA polypeptide comprises an amino acid sequence that is at least 97% identical to an amino acid sequence corresponding to residues 30-110 of SEQ ID NO: 9, and wherein the ActRIIA polypeptide binds to activin and/or GDF11.
US Pat. No. 11,066,598

DYE-SENSITIZED UPCONVERSION NANOPHOSPHOR

Korea Institute of Scienc...


1. A dye-sensitized upconversion nanophosphor, comprising:a core;
a first shell surrounding at least part of the core; and
an organic dye bonded to a surface of the nanophosphor which has an absorption band ranging from 650 nm to 850 nm and which is excited in a near-infrared region to emit visible light,
wherein the core is made of a fluoride-based material co-doped with Yb3+ and Er3+ and expressed by Chemical Formula 1 below,LiGdxL1-x-y-zF4:Yb3+y,Er3+z,??Chemical Formula 1

where x denotes a real number satisfying 0?x?0.6, y denotes a real number satisfying 0 wherein the first shell is made of a fluoride-based crystalline material co-doped with Nd3+ and Yb3+ and expressed by Chemical Formula 2 below,LiY1-p-q-rMrF4:Nd3+p,Yb3+q,??Chemical Formula 2

where p denotes a real number satisfying 0
US Pat. No. 11,065,305

COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION INCLUDING AT LEAST HUMAN INSULIN A21G AND A GLUCAGON SUPPRESSOR WITH PRANDIAL ACTION

ADOCIA, Lyons (FR)


1. A composition in the form of an injectable aqueous solution, the pH of which is from 3.5 to 4.4, including at least human insulin A21G referred to as regular in a range from 100 to 300 U/ml and pramlintide at a concentration of between 0.4 to 3.0 mg/ml.
US Pat. No. 11,066,341

MICROBIAL CONSORTIA

AMVAC Chemical Corporatio...


1. A method comprising:mixing a chitin-containing biological source with a composition comprising cells of five or more microbial species selected from Bacillus spp., Lactobacillus spp., Clostridium spp., Streptomyces spp., Virgibacillus spp., Brevibacillus spp., Paenibacillus spp., Oceanobacillus spp., Lysinibacillus spp., Acetobacter spp., Rummeliibacillus spp., and Candida spp., wherein each of the five or more microbial species has a 16S rDNA sequence with at least 99% sequence identity to one of SEQ ID NOs: 1-17 to form a mixture;
fermenting the mixture; and
separating the fermented mixture into solid, aqueous, and lipid fractions.

US Pat. No. 11,066,599

PRODUCTION METHOD FOR CARBON-BASED LIGHT-EMITTING MATERIAL

NISSAN CHEMICAL INDUSTRIE...


1. A method for producing a carbonaceous luminescent material that, when exposed to excitation light having a wavelength of 300 to 600 nm, emits light having a wavelength of 550 to 700 nm, which method comprises the step of mixing together and heating an ascorbic acid-containing starting material, an inorganic acid-containing acid catalyst and a solvent,wherein the solvent consists of water.

US Pat. No. 11,067,886

REFLECTIVE PHOTOMASK BLANK AND REFLECTIVE PHOTOMASK

TOPPAN PRINTING CO., LTD....


1. A reflective photomask blank for producing a reflective photomask for pattern transfer using extreme ultraviolet light as a light source, the reflective photomask blank comprising:a substrate;
a reflective layer including a multilayer film and formed on the substrate; and
a light absorbing layer formed on the reflective layer, the light absorbing layer including a tin oxide film with a film thickness of 17 nm or more and less than 25.0 nm; wherein
an atomic ratio (O/Sn) of oxygen (O) to tin (Sn) contained in the tin oxide film is 1.0 or more and 2.0 or less; and
given that Rm is a reflected light intensity from the reflective layer and that Ra is a reflected light intensity from the light absorbing layer, an OD (Optical Density) defined by a formula (1) below is 1 or more and less than 1.5,OD=?log(Ra/Rm)??(1).


US Pat. No. 11,065,307

THERAPEUTIC FUSION PROTEIN COMPRISING AN ALPHA-N-ACETYLGLUCOSAMINIDASE AND A LYSOSOMAL TARGETING MOIETY

Shire Human Genetic Thera...


1. A therapeutic fusion protein comprisingan alpha-N-acetylglucosaminidase (Naglu) domain;a lysosomal targeting moiety, and

a linker between the lysosomal targeting moiety and the Naglu domain;wherein the lysosomal targeting moiety is a peptide that binds cation-independent mannose-6-phosphate receptor (CI-MPR) or bis-phosphorylated oligosaccharides;

wherein the Naglu domain has alpha-N-acetylglucosaminidase activity and comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1;
wherein the linker comprises the amino acid sequence of residues 721-777 of SEQ ID NO: 6;
wherein once administered intrathecally, the therapeutic fusion protein is targeted to lysosomes.

US Pat. No. 11,066,343

METHOD FOR PRODUCING P-XYLENE

ENEOS CORPORATION, Tokyo...


1. A method for producing p-xylene, comprising:providing a C4 fraction comprising at least isobutene as a product formed by fluidized catalytic cracking of a heavy oil fraction;
bringing a first raw material comprising the isobutene into contact with a dimerization catalyst to produce a C8 component comprising a dimer of the isobutene; and
bringing a second raw material comprising the C8 component into contact with a dehydrogenation catalyst to produce p-xylene through a cyclization/dehydrogenation reaction of the C8 component, wherein
the dehydrogenation catalyst comprises supported metals comprisingat least one metal element in group 14 and
Pt

supported on a support comprisingAl and
at least one metal element in group 2, and

the molar ratio of the at least one metal element in group 14 to Pt (number of moles of at least one metal element in group 14/number of moles of Pt) in the dehydrogenation catalyst is from 5.4 to 15, and
the content of the at least one metal element in group 14 in the dehydrogenation catalyst is 4 mass % or more based on the total mass of the dehydrogenation catalyst.

US Pat. No. 11,065,308

METHODS AND COMPOSITIONS FOR CNS DELIVERY OF HEPARAN N-SULFATASE

Shire Human Genetic Thera...


1. A method of treating Sanfilippo A Syndrome comprising a step ofadministering intrathecally to a subject in need of treatment a formulation comprising a heparan N-sulfatase (HNS) protein at a concentration at or greater than 5 mg/ml, and no greater than 50 mM phosphate.

US Pat. No. 11,065,309

SUBCUTANEOUS THERAPEUTIC ENZYME FORMULATIONS, USES, AND METHODS FOR GENERATING THEREOF

KINETIQ THERAPEUTICS, LLC...


1. A composition for subcutaneous or intradermal delivery comprising:a lysosomal storage disorder replacement enzyme (LSDRE) and a dispersing agent together in a stable formulation,
wherein the dispersing agent is in an amount corresponding to greater than 1000 U and less than 10,000 U per single unit dose for facilitating subcutaneous or intradermal delivery of a therapeutically effective amount of LSDRE.

US Pat. No. 11,066,603

FIRE INSULATION MATERIAL


1. A fire insulation material comprising:a precursor including;
(i) a cement, in an amount of between 10-30% w/w of the precursor,
(ii) at least one of aluminium hydroxide, magnesium hydroxide, huntite, and hydromagnesite, in an amount of between 60-90% w/w of the precursor, and
(iii) a cement additive comprising one or more of (a) styrene butadiene, in the form of a wet resin, and (b) a polymer powder or dispersion.

US Pat. No. 11,071,241

ELECTROMAGNETIC SHIELDING METHOD USING GRAPHENE AND ELECTROMAGNETIC SHIELDING MATERIAL

Graphene Square Inc., Se...


1. A method for shielding electromagnetic waves by using graphene, the method comprising:forming 2 to 4 layers of graphene outside or inside a device having electromagnetic wave generating source to shield electromagnetic waves by the graphene,
wherein the 2 to 4 layers of graphene are formed on a first side of a substrate,
wherein an adhesive layer is formed on the graphene,
wherein a first protective layer is formed on the adhesive layer, the first protective layer forming a first outer layer of an electromagnetic wave shielding film,
wherein a second protective layer is formed on a second side of the substrate, the second side opposite the first side, wherein the second protective layer forms a second outer layer of the electromagnetic wave shielding film,
wherein a sheet resistance of the graphene is between 120 ?/sq to 30 ?/sq,
wherein the electromagnetic wave shielding film is configured to shield from an electromagnetic wave with a broad frequency band between 2 GHz to 18 GHz, and,
wherein the first protective layer and the second protective layer are each independently formed from a material selected from a group consisting of: polyethylenes, polypropylenes, polyimides, polyethylene terephthalates, polyesters, polyethers, sulfonated polyethylenes, epoxys, phenol resins, polybutylene terephthalates, polyethylene naphthalates, and polybutylene naphthalates, and
wherein the graphene is doped with AuCl3—CH3NO.

US Pat. No. 11,065,310

COMPOSITIONS AND METHODS FOR THROMBOEMBOLISM DISSOLUTION

NATTOCAT, LLC, Fairfax S...


1. A method of dissolving a feline thrombus comprising:administering to the feline from 10 to 30 tablets of an enzymatic formula containing nattokinase and an enteric coating;
wherein each tablet comprises nattokinase at 37.5 mg/750 fibrinolytic units.

US Pat. No. 11,065,570

FILTER MEDIUM AND A USE THEREOF


1. A filter medium for filtering a fluid, the filter medium being at least formed of a prefilter substrate laminated by means of a hot melt binder or adhesive with a fine-filter substrate such that the pre-filter substrate comprises synthetic fibers and a first binder, the pre-filter substrate works as a combined surface and depth filter substrate, and the fine-filter substrate comprises a second binder and at least one of synthetic fibers and inorganic fibers, characterized in the mean flow pore size for the pre-filter substrate ranging from 8 to 10 micrometers, for the fine-filter substrate from 3 to 7 micrometers and for the laminated filter medium from 1.5 to 6 micrometers.
US Pat. No. 11,065,311

RETROVIRAL VECTOR WITH MINI-PROMOTER CASSETTE

DENOVO BIOPHARMA LLC, Sa...


1. A recombinant replication competent gammaretrovirus comprising:a retroviral GAG protein;
a retroviral POL protein;
a retroviral envelope;
a retroviral polynucleotide comprising Long-Terminal Repeat (LTR) sequences at the 3? end of the retroviral polynucleotide sequence, a promoter sequence at the 5? end of the retroviral polynucleotide, said promoter being suitable for expression in a mammalian cell, a gag nucleic acid domain, a pol nucleic acid domain and an env nucleic acid domain;
a therapeutic cassette comprising at least one mini-promoter cassette having a mini-promoter that is regulated by an RNA polymerase II, wherein the mini-promoter is about 70-500 bp in length and operably linked to a heterologous polynucleotide, wherein the therapeutic cassette is positioned 5? to the 3? LTR and 3? to the env nucleic acid domain encoding the retroviral envelope, and wherein when only one mini-promoter cassette is present the heterologous polynucleotide is 1.2kb to 2.0 kb in length; and
cis-acting sequences necessary for reverse transcription, packaging and integration in a target cell, and wherein the mini-promoter comprises an RSV promoter.

US Pat. No. 11,067,892

PHOTOSENSITIVE CTP FLEXOGRAPHIC PRINTING ORIGINAL PLATE

TOYOBO CO., LTD., Osaka ...


1. A photosensitive CTP flexographic printing original plate, characterized in that, it comprises at least a support, a photosensitive resin layer and a heat-sensitive mask layer which are sequentially layered, that the heat-sensitive mask layer contains a methoxymethylated polyamide resin (A) and a water-soluble polyamide resin (B) containing a basic nitrogen atom in a molecule, and that a glass transition point of the polyamide resin (A) is 0° C. to 30° C.
US Pat. No. 11,066,349

METHOD FOR SEPARATING ESSENTIAL OILS FROM BIOMASS

Oil Extraction Company, ...


1. A continuous process for extracting essential oils from biomass, comprising the steps of:providing an elongated, vertically-oriented extraction vessel, comprising an inner draft tube for receiving biomass at an upper end thereof, an outer tube of larger diameter than said inner draft tube and located concentrically around said inner draft tube and defining an outlet weir at its upper extremity, a conical midsection affixed to a lower end of said outer tube, and a lower tube affixed to a lower end of said conical midsection and having an outlet at a lower end thereof,
providing a conveyor in sealed communication with said outlet of said lower tube, said conveyor being inclined upwardly from said outlet of said lower tube, being maintained at an angle to the vertical and having an upper outlet above said outlet weir,
introducing biomass to the upper end of said inner draft tube, such that the biomass migrates downwardly,
introducing a solvent for the essential oils at a lower extremity of said reactor vessel,
allowing the solvent to migrate upwardly through the biomass, absorbing the essential oils therefrom, forming a liquor;
collecting the liquor at said overflow weir,
allowing the biomass to exit the lower tube at the outlet thereof and be deposited in said conveyor, and
driving said conveyor to propel biomass from said outlet of said lower tube to the upper outlet of said conveyor.

US Pat. No. 11,065,313

MODIFIED YEAST-BRACHYURY IMMUNOTHERAPEUTIC COMPOSITIONS

GlobeImmune, Inc., Louis...


1. A yeast-Brachyury immunotherapeutic composition, wherein the immunotherapeutic composition comprises:a) a yeast;
b) at least one modified Brachyury antigen expressed by the yeast, wherein the modified Brachyury antigen has an amino acid sequence comprising SEQ ID NO:10, positions 2-410 of SEQ ID NO:10, SEQ ID NO:13, or positions 2-410 of SEQ ID NO:13; and wherein the modified Brachyury antigen has an amino acid sequence that differs from a wild-type Brachyury amino acid sequence of SEQ ID NO:4 by a deletion of positions 198 through 222 of the wild-type Brachyury, wherein the Brachyury antigen has a disrupted DNA binding site as compared to the wild-type Brachyury.

US Pat. No. 11,066,350

PROCESS FOR DEHYDRATING METHANOL TO DIMETHYL ETHER

BP P.L.C., London (GB) B...


1. A process comprising dehydrating methanol to dimethyl ether product in the presence of a catalyst and a promoter, wherein the catalyst is at least one aluminosilicate zeolite and the promoter is at least one(i) aldehyde of formula R1CHO (Formula I)
wherein R1 is a C3-C11 alkyl group or a C3-C11 alkyl group in which 3 or more carbon atoms are joined to form a ring; or
(ii) acetal derivative of an aldehyde of Formula I; and

wherein the molar ratio of promoter to methanol is maintained at 0.1 or less.
US Pat. No. 11,065,314

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST BREAST CANCER AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...


1. A method of treating cancer in a HLA-A*02+ patient having a cancer overexpressing a MXRA5 polypeptide comprising the amino acid sequence of SEQ ID NO: 49 and presenting at its surface a peptide consisting of SEQ ID NO: 49 in complex with an MHC class I molecule, said method comprising administering to said patient an effective amount of activated antigen-specific CD8+ cytotoxic T cells to selectively eliminate cancer cells,wherein said activated antigen-specific CD8+ cytotoxic T cells are produced by contacting CD8+ cytotoxic T cells with an antigen presenting cell presenting at its surface a peptide consisting of SEQ ID NO: 49 in complex with an MHC class I molecule in vitro,
wherein the cancer is selected from the group consisting of breast cancer, small cell lung cancer, kidney cancer, stomach cancer, pancreatic cancer, non-Hodgkin lymphoma, melanoma, esophageal cancer, uterine cancer, gallbladder cancer, and bile duct cancer.

US Pat. No. 11,066,608

LIGHT ALKANES TO LIQUID FUELS

Phillips 66 Company, Hou...


1. A method for upgrading light hydrocarbons to a liquid transportation fuel or a value-added chemical, comprising:a) providing a light alkanes feed stream comprising alkanes containing from two to seven carbon atoms, wherein at least 50 wt. % of the light alkanes feed stream comprises alkanes and at least 90 mol. % of the alkanes contain from two to four carbon atoms;
b) contacting the light alkanes feed stream with an aromatization catalyst comprising at least one zeolite that is impregnated with at least one metal, wherein the contacting occurs in an aromatization reactor that is maintained at a temperature and a pressure that selectively facilitates conversion of alkanes containing four or more carbon atoms to olefins and aromatics by the aromatization catalyst, wherein the conversion produces a first effluent comprising light olefins, aromatics, hydrogen and unconverted light alkanes that contain three or less carbon atoms;
c) separating the first effluent in a first separator to produce a first condensed liquid hydrocarbons comprising olefins and aromatics containing at least four carbon atoms, and an uncondensed light hydrocarbons predominantly comprising unconverted alkanes and olefins containing two or three carbon atoms;
d) thermally cracking the uncondensed light hydrocarbons in a cracking reactor to produce a second effluent predominantly comprising olefins containing from two to four carbon atoms, methane and hydrogen;
e) separating the second effluent in a second separator to produce a second condensed liquid hydrocarbons comprising hydrocarbons containing at least five carbon atoms, a light olefin stream comprising olefins contacting from two to four carbon atoms hydrogen, methane and residual alkanes containing two or three carbon atoms;
f) contacting the light olefin stream with an oligomerization catalyst in an oligomerization reactor that is maintained at a temperature and pressure that facilitates the catalytic conversion of the light olefin stream by an oligomerization catalyst to produce a third effluent comprising monocyclic aromatics, alkanes containing at least five carbon atoms, light alkanes containing from one to four carbon atoms and hydrogen;
g) separating the third effluent in a third separator to produce a fuel gas stream comprising light alkanes containing from one to four carbon atoms and hydrogen and a third condensed liquid hydrocarbons comprising alkanes, olefins and aromatics containing at least five carbon atoms that possess the characteristics of at least one of: a liquid transportation fuel component and a value-added chemical intermediate.

US Pat. No. 11,067,895

METHOD AND STRUCTURES FOR PERSONALIZING LITHOGRAPHY

International Business Ma...


1. A method for printing a pattern on a substrate comprising:providing a primary mask comprising a plurality of common features of a chip at a given mask level;
exposing a photoresist layer located on the substrate through the primary mask to print the plurality of common features in the photoresist layer;
providing a secondary mask comprising a library of different and selectable functional features for modifying selected common features of the plurality of common features printed in the photoresist layer at the given mask level according to a chip design;
first selecting a first functional feature in the library of the functional features of the secondary mask;
first exposing the photoresist layer through the secondary mask to print the first selected functional feature in the photoresist layer and to modify a functionality or configuration of at least one first common feature of the plurality of common features printed in the photoresist layer into at least one first new feature comprising a combination of the least one first common feature and the first selected functional feature;
second selecting, utilizing the same secondary mask as used during the first selecting and first exposing, a second functional feature in the library of the functional features of the secondary mask according to the chip design; and
second exposing the photoresist layer through the secondary mask to print the second selected functional feature in the photoresist layer and to modify a functionality or configuration of at least one second common feature of the plurality of common features printed in the photoresist layer into a second new feature comprising a combination of the least one second common feature and the second selected functional feature.

US Pat. No. 11,065,315

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...


1. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 6, wherein said cancer is prostate cancer, liver cancer, or pancreatic cancer.
US Pat. No. 11,066,352

PROCESSES OF MAKING L-ORNITHINE PHENYLACETATE

Ocera Therapeutics, Inc.,...


1. A process of making L-ornithine phenylacetate, comprising:intermixing L-ornithine hydrochloride and potassium hydroxide in a first solvent to form a first reaction mixture, wherein the first solvent comprises water;
adding a second solvent to said first reaction mixture, wherein the second solvent comprises ethanol;
isolating potassium chloride from said first reaction mixture;
intermixing phenylacetic acid with said first reaction mixture to form a second reaction mixture; and
isolating a composition comprising L-ornithine phenylacetate from said second reaction mixture.

US Pat. No. 11,065,316

PEPTIDES AND T CELLS FOR USE IN IMMUNOTHER[[R]]APEUTIC TREATMENT OF VARIOUS CANCERS

IMMATICS BIOTECHNOLOGIES ...


1. A method for treating a patient who has cancer, comprising administering to the patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 174 in a complex with HLA-A*24,wherein the activated T cells are produced by contacting T cells with the peptide loaded human class I molecule expressed on the surface of an antigen presenting cell for a period of time sufficient to activate the T cells,
wherein said cancer is glioblastoma or non-small cell lung cancer.

US Pat. No. 11,065,577

PROCESS FOR THE PRODUCTION OF COPPER SULFIDE

Petroliam Nasional Berhad...


1. A process for the removal of mercury from a mercury-containing hydrocarbon fluid stream comprising the steps of:(i) contacting the mercury-containing hydrocarbon fluid stream with a sorbent comprising copper sulfide of the formula CuxSy, wherein x and y are integer or non-integer values; and
(ii) separating a fluid product from the sorbent, wherein the fluid product has a reduced mercury content compared to the mercury-containing hydrocarbon fluid stream;
wherein the copper sulfide is obtained or obtainable by a process comprising the following steps:(a) reacting an aqueous solution of a copper salt with a molar excess of a sulfiding agent so as to precipitate copper sulfide from the solution;
(b) isolating the copper sulfide precipitate from the reaction mixture; and
(c) drying the copper sulfide precipitate at a temperature of less than 100° C.


US Pat. No. 11,066,353

ANTIGEN DELIVERY VECTORS AND CONSTRUCTS

Altimmune UK Ltd, Leeds ...


1. A multi-component pharmaceutical composition configured for intracellular delivery of T cell epitopes to induce a cell-mediated immune response, the pharmaceutical composition comprising:two to about 20 different types of fluorocarbon peptide constructs, wherein each different type of fluorocarbon peptide construct comprises:a fluorocarbon chain from 3 to 30 carbon atoms, wherein one or more fluorine moieties is optionally substituted with chlorine, bromine or iodine or a methyl group; and,
a peptide comprising one or more CD8+T cell epitopes including at least two MHC class I or II epitopes, the peptide being coupled to the fluorocarbon vector via either an N-terminus or C-terminus of the peptide and the fluorocarbon vector;

wherein the fluorocarbon peptide constructs are comprised within micelles, each different type of fluorocarbon peptide construct comprises a different peptide sequence, and the fluorocarbon chain enhances CD8+T cell response against the peptide; and,
one or more pharmaceutical acceptable carriers, excipients, diluents or adjuvants.

US Pat. No. 11,065,317

HEAT SHOCK PROTEIN-BINDING PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF

AGENUS INC., Lexington, ...


1. An isolated polypeptide comprising:(a) an antigenic peptide comprising one or more major histocompatibility complex (MHC)-binding epitopes; and
(b) a heat shock protein (HSP)-binding peptide comprising the amino acid sequence of X1LX2LTX3 (SEQ ID NO: 1), wherein X1 is W or F; X2 is R or K; and X3 is W, F, or G.

US Pat. No. 11,065,318

YEAST-MUC1 IMMUNOTHERAPEUTIC COMPOSITIONS AND USES THEREOF

GlobeImmune, Inc., Louis...


1. A combination immunotherapeutic composition, wherein the immunotherapeutic composition comprises:a) a yeast-MUC1 immunotherapeutic composition comprising:i) a yeast vehicle; and
ii) a fusion protein expressed by the yeast vehicle, wherein the fusion protein comprises a MUC1 antigen comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:25 and wherein the MUC1 antigen comprises at least 2 amino acid substitutions selected from the group consisting of L184, Y232, L233, V240, Y241, L242, Y483, V497, L535, F536 and Y551 with reference to SEQ ID NO:25; and

b) a virus-based immunotherapeutic composition comprising a recombinant viral vector encoding a cancer antigen.

US Pat. No. 11,065,319

METHODS FOR DIAGNOSING AND REDUCING INCIDENCES OF CARDIAC ALLOGRAFT REJECTION

3DT Holdings, LLC, San D...


1. A noninvasive method of screening a cardiac allograft recipient for being at-risk for developing cardiac allograft vasculopathy, the method comprising the steps of:withdrawing at least one biological sample from a cardiac allograft recipient; and
analyzing the at least one biological sample for one or more biomarkers indicative of the presence of fibrin deposits within the cardiac allograft microvasculature;
wherein detection of the one or more biomarkers indicates that the cardiac allograft recipient is at-risk for developing the fibrin deposits within the cardiac allograft vasculature indicative of cardiac allograft vasculopathy;
wherein the one or more biomarkers is/are selected from the group consisting of an elevated level of cardiac troponin I, reduced anticoagulant and fibrinolytic capacities of the serum, detection of up-regulation of endothelial intercellular adhesion molecule-1 (ICAM-1) expression, and detection of an elevated nuclear factor-kappa B (NF-KB) nuclear expression; and
wherein if the cardiac allograft recipient is at-risk of developing the fibrin deposits within the cardiac allograft vasculature indicative of cardiac allograft vasculopathy, the method further comprises the step of:
administering a therapeutically effective amount of phosphorylcholine to the cardiac allograft recipient to treat and/or prevent cardiac allograft vasculopathy, which selectively enhances a natural antibody-mediated innate immune response in the cardiac allograft recipient by increasing levels of immunoglobulin M and/or immunoglobulin G anti-phosphorylcholine natural antibodies in an allograft recipient's serum.

US Pat. No. 11,065,320

PRIME TARGET

OXFORD UNIVERSITY INNOVAT...


1. A kit comprising (a) a first composition comprising a viral vector encoding an epitope of a first liver disease antigen, wherein the epitope is a CD8+ T cell epitope, said viral vector being selected from the group consisting of: adenoviral vector, adeno-associated viral vector and poxviral vector; and (b) a second composition comprising a viral vector encoding an epitope of a second liver disease antigen, wherein the epitope is a CD8+T cell epitope, the viral vector being selected from the group consisting of: adenoviral vector, adeno-associated viral vector and poxviral vector; wherein (i) the second composition is formulated for i.v. or i.p. administration, and (ii) the kit comprises a device for i.v. or i.p. administration;wherein the epitope of a first liver disease antigen and the epitope of a second liver disease antigen may be the same or different epitope or antigen; and
wherein said first and second compositions are formulated differently for administration by different routes and the kit comprises devices for administration of said first and said second compositions by different routes.

US Pat. No. 11,066,614

HYDROCARBON MARINE FUEL OIL

INFINEUM INTERNATIONAL LI...


1. A liquid hydrocarbon marine fuel oil comprising a marine distillate fuel or a heavy fuel oil or a blend thereof, the fuel oil comprising an additive combination consisting of:(A) a polyalkenyl-substituted carboxylic acid or anhydride; and
(B) a metal detergent system comprising a hydrocarbyl-substituted hydroxybenzoate metal salt or a hydrocarbyl-substituted sulfonate metal salt or a mixture of both salts or complex thereof;

where the mass:mass ratio of (A) to (B) is in the range of 20:1 to 1:20, and a treat rate of the additive combination is in the range of 10 to 1,000 ppm by mass.
US Pat. No. 11,069,445

MEDICAL DIAGNOSIS ASSISTANCE METHOD

SORBONNE UNIVERSITE, Par...


1. A device-implemented method for assistance with the establishment of a diagnosis of a patient, comprising:providing a device that incorporates a computerized knowledge database (10) of a medical ontology (12) that includes a first list (121) of signs (Si) forming a “sign” class, a list (122) of pathological states (Dj) forming a “pathological state” class, a first set (124) of logical relationships between the signs and the pathological states, each logical relationship of said first set (124) establishing a correlative link between a sign and a pathological state, a second list (123) of technical methods for acquiring medical images (Mk) forming an “imaging” class, each of said technical methods for acquiring medical images (Mk) defining a type of technology for acquisition of medical images and a positioning of the medical image on the patient, and a third set (126) of logical relationships between the signs and the technical methods for acquiring medical images (Mk), each logical relationship of said third set (126) defining a technical method for acquiring a medical image that makes possible an observation of a sign;
receiving, at the device from an operator of the device, one or more identified signs;
searching (503), carried out by the device, for potential pathological states, in which all of the pathological states linked by a correlative link to at least one of the identified signs are sought in the pathological state class by means of the first set (124) of logical relationships, said pathological states forming the potential pathological states;
identifying (504), carried out by the device, potential signs in which, for each potential pathological state, all of the signs linked by a correlative link to said potential pathological state are identified in the sign class by means of the first set (124) of logical relationships, said signs forming the potential signs; and
identifying (505), carried out by the device, technical methods for acquisition of interest, in which for each potential sign, all of the technical methods for acquiring medical images that make possible to observe said potential sign are identified in the imaging class by means of the third set (126) of logical relationships, said technical methods for acquiring medical images forming the technical methods for acquisition of interest.

US Pat. No. 11,065,321

LIVE ATTENUATED BACTERIAL STRAIN AND ITS USE AS A VACCINE

CENTRE DE COOPERATION INT...


1. A vaccine composition comprising a bacterial strain selected from the group consisting of an Ehrlichia strain, an Anaplasma strain, a Rickettsia strain, an Orientia strain, a Bartonella strain, and a Brucella strain, with a deleted or inactive ntrX gene.
US Pat. No. 11,066,615

COPOLYMERS OF BICYCLIC (METH)ACRYLATE AND ALKYL (METH)ACRYLATE AND THEIR USE AS RHEOLOGY MODIFIERS IN FUELS

NOURYON CHEMICALS INTERNA...


1. A solid copolymer formed from the following monomers:more than 20% and up to 81.5% by weight, based on the weight of all monomers, of at least one bicyclic (meth)acrylate ester,
7% to 85% by weight of at least one C1-C7-alkyl (meth)acrylate based on the weight of all monomers,
0% up to 40% by weight of at least one aromatic vinyl monomer based on the weight of all monomers, and
optionally other ethylenically unsaturated monomers,
wherein, if present, divinylbenzene is at an amount below 5% by weight, based on the weight of all monomers, and
wherein the copolymer is soluble in B7 diesel fuel, has a weight averaged molecular weight from 2,000,000 to 10,000,000 Daltons, and has a glass transition temperature (Tg) of from 50 to 190° C.

US Pat. No. 11,065,322

BACTERIAL VACCINE COMPONENTS AND USES THEREOF


1. A pharmaceutical composition comprising:(i) at least one polypeptide, wherein said polypeptide is:
(a) a polypeptide encoded SACOL0442, wherein the polypeptide comprises residues 36-203 of SEQ ID NO: 37 or SEQ ID NO: 48;
(b) a polypeptide comprising an amino acid at least 95% identical overall to the full-length of the polypeptide of (a);
(c) a polypeptide comprising an immunogenic fragment of (a) or (b) wherein the fragment consists of at least 14 consecutive amino acids of SEQ ID NO: 37 or SEQ ID NO: 48;
(d) any combination of (a) to (c) and
(ii) a pharmaceutically acceptable excipient; and
(iii) and adjuvant.

US Pat. No. 11,065,841

ASPHALTIC SHEET MATERIALS INCLUDING EXPANDABLE GRAPHITE

Firestone Building Produc...


1. A method for producing an asphaltic composite, the method comprising:(i) providing an asphaltic sheet by saturating a fabric with a molten asphaltic composition to thereby form the asphaltic sheet, where the asphaltic sheet has first and second opposed planar surfaces;
(ii) dropping a material consisting of solid particulates onto the first planar surface of the asphaltic sheet, where the solid particulates include expandable graphite particles characterized by an onset temperature of at least 160° C., where said step of dropping takes place while the asphaltic composition is in a molten or semi-molten state so that the expandable graphite particles at least partially embed in to the asphaltic composition and the asphaltic composition serves to hold at least some of the expandable graphite particles to the first planar surface of the asphaltic sheet;
(iii) laminating a polymeric film to the first planar surface of the asphaltic sheet to thereby sandwich the expandable graphite between the first planar surface of the asphaltic sheet and the polymeric film; and
(iv) removably securing a release member to the second planar surface of the asphaltic sheet.

US Pat. No. 11,065,323

PURIFICATION METHOD

GLAXOSMITHKLINE BIOLOGICA...


1. A process for purifying group A streptococcus (GAS) carbohydrate, comprising:a first step of filtration or ultrafiltration of an aqueous suspension of GAS carbohydrate, polyrhamnose, and hyaluronic acid, wherein said aqueous suspension was prepared by reductive acid treatment of GAS bacteria such that the GAS carbohydrate, polyrhamnose and the hyaluronic acid were released from the GAS bacteria;
a second step of anionic exchange chromatography on a mixture comprising the GAS carbohydrate, polyrhamnose and the hyaluronic acid from the first step, wherein the anionic exchange chromatography is performed under conditions that allow flow through of the GAS carbohydrate and less than 1% by weight of the hyaluronic acid, and
a third step, which comprises tangential flow filtration using a 5 or 10 kDa cut-off membrane of a mixture comprising the GAS carbohydrate from the second step,
wherein the process yields a purified GAS carbohydrate comprising a level of hyaluronic acid contamination that is: a) less than 80 ng/ml; or b) less than 1% by weight of the hyaluronic acid relative to the weight of the GAS carbohydrate; and a polyrhamnose impurity of less than 20% by weight of the polyrhamnose relative to the weight of the GAS carbohydrate.

US Pat. No. 11,065,324

COMBINATION VACCINE FOR SWINE

Intervet, Inc., Madison,...


1. A combination vaccine comprising non-replicating antigen from porcine circovirus type 2 (PCV2) and live porcine reproductive and respiratory syndrome virus (PRRSV), wherein the vaccine is an oil-in-water emulsion comprising squalane and vitamin E-acetate; wherein the oil-in-water emulsion is a submicron emulsion.
US Pat. No. 11,065,585

SYNTHETIC MEMBRANES AND METHODS OF USE THEREOF

Rensselaer Polytechnic In...


1. A method of making a synthetic membrane for recovering a target via separation, the method comprising:providing a skin support layer including polysulfone, cellulose, cellulose acetate, polyvinylidene fluoride, polyimide, polyethylene, polypropylene, polyacrylonitrile, polyethylene terephthalate, or combinations thereof;
providing a light-sensitive poly(ether sulfone) membrane support layer to the skin support layer;
irradiating a surface of the light-sensitive poly(ether sulfone) membrane support layer; and
contacting a monomer solution with the surface of the light-sensitive membrane support layer, the monomer solution comprising vinyl monomers and a solvent.

US Pat. No. 11,065,843

MULTI-LAYERED FINISHES FOR CAN ENDS

Novelis Inc., Atlanta, G...


1. A multi-layered finish coated product, comprising:an aluminum substrate comprising a 3xxx series aluminum alloy or a 5xxx series aluminum alloy, wherein the aluminum substrate comprises a beverage can end;
a base coating layer adhered to the aluminum substrate, wherein the base coating layer has a thickness of 0.1 ?m to 15 ?m; and
a clear coating layer comprising effects particles, wherein the clear coating layer is adhered to the base coating layer, and wherein the clear coating layer has a thickness of 1 ?m to 20 ?m.

US Pat. No. 11,066,620

LUBRICANT COMPOSITION

BASF SE, Ludwigshafen am...


1. A lubricant composition comprisinga base oil,
one or more antioxidants selected from a group consisting of N-?-naphthyl-N-phenylamine antioxidants and diphenylamine antioxidants; and
a sulfur-containing additive comprising a mixture of sulfurized isobutylene compounds having from 1 to 5 sulfur atoms, wherein the mixture of sulfurized isobutylene compounds comprises one or more of:from about 32.5% to about 42.5% sulfurized isobutylene with two sulfur atoms,
from about 5% to about 15% sulfurized isobutylene with four sulfur atoms, or
from about 1% to about 11% sulfurized isobutylene with five sulfur atoms, and wherein a total sulfur concentration provided by the sulfur-containing additive ranges from about 50 ppm to about 1000 ppm by weight, based on the total weight of the lubricant composition.


US Pat. No. 11,065,327

HUMAN ROTAVIRUS STRAINS AND VACCINES

The United States of Amer...


1. An isolated rotavirus non-structural protein (NSP) protein, whereina) the NSP protein is a NSP1 protein that has greater than 95% identity to SEQ ID NO: 3, and wherein amino acid 122 is an arginine;
b) the NSP protein is a NSP5 protein that i) has greater than 95% identity to SEQ ID NO: 15, and wherein amino acid 45 is an isoleucine, or ii) has greater than 95% identity to SEQ ID NO: 96, and wherein amino acid 60 is a valine; or
c) the NSP protein is a NSP2 protein that has greater than 95% identity to SEQ ID NO: 78, and wherein amino acid 142 is a tyrosine.

US Pat. No. 11,065,846

POLYMER FILM AND USES OF THE SAME

CHANG CHUN PETROCHEMICAL ...


1. A polymer film, which comprises polyvinyl acetal, wherein:the polymer film has a 45-100° C. dimensional variability ranging from 20 ?m to 50 ?m; and
at least one surface of the polymer film has a surface roughness Rz ranging from 30 ?m to 55 ?m,
wherein the 45-100° C. dimensional variability is a thickness variation of the polymer film between 45° C. and 100° C.,
wherein the polyvinyl acetal has a viscosity ranging from 70 cps to 110 cps,
wherein the polyvinyl acetal comprises 11 mol % to 20 mol % of polyvinyl acetal with a molecular weight lower than 50,000 daltons.

US Pat. No. 11,066,621

LUBRICATING OIL COMPOSITION

KYODO YUSHI CO., LTD., F...


1. A lubricating oil composition not containing ZnDTP but comprising the following components (a) to (c):(a) a base oil;
(b) molybdenum dialkyldithiocarbamate; and
(c) an organic acid metal salt compound which is nickel 2-ethylhexanoate,
wherein a content of the molybdenum dialkyldithiocarbamate in the composition is 0.1 to 0.5 mass %, and
a content of the organic acid metal salt compound in the composition is 200 to 500 ppm in terms of nickel concentration, and
wherein the lubricating oil composition is free of an amine-based antioxidant.

US Pat. No. 11,065,328

VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS


1. A safe and efficacious vaccine against infectious bronchitis virus (IBV), comprising:an IBV in an amount effective to reduce the incidence or severity of tracheal lesions in an animal immunized with the IBV, relative to a non-immunized control animal of the same species, when subsequently infected with a pathogenic IBV strain; and
a pharmaceutically acceptable carrier,
wherein the IBV comprises an inactivated ORF 5a that attentuates a virulent parent strain.

US Pat. No. 11,066,881

METHOD AND COMPOSITION FOR STABILIZATION OF DRILL CUTTINGS


1. A method for composing an admixture for stabilization of drill cuttings comprises:providing precipitated calcium carbonate (PCC), a synthetically formed CaCO3;
drying the PCC to a moisture level of about 10% or less; and
blending the dried PCC with hydrated lime, also known as calcium hydroxide {Ca(OH)2}, to compose a generally uniform admixture, the hydrated lime, not to exceed 50%.

US Pat. No. 11,065,329

HUMAN HERPESVIRUS IMMUNOTHERAPY

The Council of the Queens...


1. A protein comprising amino acid sequences of a plurality of CTL epitopes and further comprising an intervening amino acid sequence between at least two of said CTL epitopes, wherein the intervening amino acid sequence consists of a proteasome liberation amino acid sequence selected from AD, K and R, and optionally a Transporter Associated with Antigen Processing (TAP) recognition motif, and wherein the protein is capable of eliciting a cytotoxic T-lymphocyte immune response upon administration to an animal as an exogenous protein.
US Pat. No. 11,065,330

INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE BY PERIPHERAL PHAGOCYTOSIS

PLS-Design GmbH, Hamburg...


1. A pharmaceutical composition for modulation of T cell and B cell responses by allergen-specific immunotherapy in combination with peripheral tolerance-inducing phagocytosis, wherein the pharmaceutical composition consists of one or more preparations, wherein the pharmaceutical composition comprises:a) at least one antigen or allergen,
b) a matrix suitable for locally restricted sustained release of therapeutically effective doses of the at least one antigen or allergen consisting of a PLGA-PEG-PLGA, which is thermogelling, wherein the gelling temperature is between 20° C. and 40° C.,
c) liposomes tailored for effective phagocytosis exposing on their surface phosphatidylserine, optionally containing OVA, said liposomes further containing said at least one antigen or allergen,
d) one or more immune modulators of phagocytosis selected from ‘find me’ signals the selected from nucleotides ATP and UTP, the one or more immune modulators of phagocytosis being released at a rate of more than 50% in 24 hours and more than 70% in 48 hours, and
e) one or more immune modulators suitable for enhancing the suppressive function of regulatory T cells at the site of antigen or allergen presentation, selected from vitamin D3 analogue Calcipotriol and IL-4/IL-13 antagonist Q, the one or more immune modulators suitable for enhancing the suppressive function of regulatory T cells being released at a rate of more than 80% in 48 hours.

US Pat. No. 11,065,849

WATERPROOFING MEMBRANE WITH A SOLID FILLER COMPONENT

SIKA TECHNOLOGY AG, Baar...


1. A membrane comprisinga barrier layer S1 having a first and a second opposing surface and
a contact layer S2 having a first and a second opposing surface,
wherein
at least a portion of the first surface of the barrier layer S1 and the second surface of the contact layer S2 are directly bonded to each other,
the barrier layer S1 has a thickness that is in a range of 0.1-10.0 mm,
the barrier layer S1 comprises a thermoplastic polymer component P1,
the first surface of the contact layer S2 has a 3D-average roughness that is in a range of 10.0-500.0 ?m,
the contact layer S2 comprises a mixture including a solid filler component F and a thermoplastic polymer component P2, and
the amount of the solid filler component F is in a range of 10.0-90.0 wt.-%, based on the total weight of the contact layer S2.

US Pat. No. 11,066,367

ELECTRON DONOR, AND METHOD FOR SYNTHESIZING 4, 4?-BIPYRIDINE USING ELECTRON DONOR

Kobelco Eco-Solutions Co....


1. An electron donor comprising a mixture of a dispersion product obtained by dispersing sodium metal or sodium metal alloy in a dispersion solvent, and 1,3-dimethyl-2-imidazolidinone and wherein a lower layer of the mixture that has been divided into two layers is used as the electron donor.
US Pat. No. 11,069,455

COMPOSITION FOR PRODUCING AN ELECTRICALLY CONDUCTIVE LAYER, IN PARTICULAR FOR AN ELECTROLUMINESCENCE DEVICE

InovisCoat GmbH, Monheim...


1. Composition for producing an electrically conductive layer according to a slotted-nozzle method, comprising2-30 wt. % of a protective colloid mixture which is soluble or dispersible in water,
1-15 wt. % of a conductive carbon modification,
5-50 wt. % of metal-coated particles,
50-90 wt. % of an aqueous solvent,
the dynamic viscosity of the conductive composition being less than 400 mPa·s,
wherein the composition comprises 0.1-10 wt. % of an ethylene-vinyl acetate copolymer.

US Pat. No. 11,065,331

IMMUNE ADJUVANT FOR CANCER

Advanced Innovation Devel...


1. A method for treating cancer or infectious disease, comprising administering an immune checkpoint blockade and an adjuvant composition to a patient in need thereof,wherein the immune checkpoint blockade comprises an anti-PD-1 antibody or an anti-PD-L1 antibody,
the adjuvant composition comprises a nucleic acid adjuvant comprising (i) a double-stranded RNA having a TLR3 activation ability, and (ii) a single-stranded oligodeoxynucleotide (single-stranded ODN) that is delivered to a dendritic cell endosome, wherein the double-stranded RNA has a nucleotide sequence comprising a sequence of continuous 40 or more bases of a nucleotide sequence represented by SEQ ID NO:1 and having a total length of 100 to 160 bases in length, and the single-stranded ODN consists of a sequence of a CpG ODN where CpG is replaced with GpC, TpC, or CpC, or a partial sequence thereof having 15 or more bases in length,
wherein the immune checkpoint blockade and the adjuvant are the sole active agents administered and results in activation of TLR3 to endosomes and/or induce tumor-specific CTLs to cause the tumor-specific CTLs to invade tumors, leading to tumor regression.

US Pat. No. 11,065,850

LAMINATE

OJI HOLDINGS CORPORATION,...


1. A laminate comprising:a fiber layer formed of cellulose fibers having a fiber width of 1000 nm or less;
a resin layer; and
an adhesive layer directly laminated between the fiber layer and the resin layer,
wherein the fiber layer comprises hydrophilic macromolecules having a molecular weight of 50,000 or more and 8,000,000 or less,
the resin layer comprises a polymer of acrylic monomers,
the adhesive layer comprises a functional group (A), which forms a covalent bond with a (meth)acryloyl group included in the resin layer, and at least one selected from a functional group (B) and a hydrolyzed group of the functional group (B), which forms a covalent bond with a hydroxy group of ultrafine cellulose fibers included in the fiber layer, and
the thickness of the fiber layer is 30 ?m or more and 500 ?m or less.

US Pat. No. 11,066,626

AMPHIPHILIC POLYSACCHARIDE DERIVATIVES AND COMPOSITIONS COMPRISING SAME


1. A composition comprising a polysaccharide derivative, wherein the polysaccharide derivative comprises a polysaccharide substituted with(a) at least one hydrophobic group that comprises a C6 to C20 aryl, benzyl, C6-C20 aryl sulfonyl, or p-toluenesulfonyl group, and
(b) at least one hydrophilic group;
wherein the polysaccharide is poly alpha-1,3-glucan or poly alpha-1,6-glucan,
and wherein the composition comprises at least one of a surfactant, enzyme, detergent builder, complexing agent, polymer, soil release polymer, surfactancy-boosting polymer, bleaching agent, bleach activator, bleaching catalyst, fabric conditioner, clay, foam booster, suds suppressor, anti-corrosion agent, soil-suspending agent, anti-soil redeposition agent, dye, bactericide, tarnish inhibitor, optical brightener, perfume, saturated or unsaturated fatty acid, dye transfer inhibiting agent, chelating agent, hueing dye, calcium cation, magnesium cation, visual signaling ingredient, anti-foam, structurant, thickener, anti-caking agent, starch, sand, or gelling agent.

US Pat. No. 11,065,332

COMBINATION THERAPY OF IMMUNOTOXIN AND CHECKPOINT INHIBITOR

Duke University, Durham,...


1. A method of treating a glioma tumor in a patient, comprising:administering to the patient an immunotoxin comprising a single chain variable region antibody fused to a PE38 truncated Pseudomonas exotoxin, wherein the single chain variable region antibody has CDR1, CDR2, and CDR3 regions as shown in SEQ ID NO: 6-11; and
administering an inhibitor of an immune checkpoint to the patient, wherein the immune checkpoint is selected from the group consisting of PD-1 and CTLA-4.

US Pat. No. 11,069,716

GLASS SUBSTRATE FOR DISPLAY AND METHOD FOR PRODUCING SAME

AvanStrate Inc., Tokyo (...


1. A glass substrate for a display composed of a glass,the glass comprising SiO2 and Al2O3, wherein the Al2O3 content is in a range of 16 to 35% by mass; and
the glass further comprising, in % by mass,
B2O3 at greater than 0% and less than 3%; and
Li2O in the range of 0 to 0.5%, and
Na2O in the range of 0 to 0.5%, and
K2O in the range of 0.1 to 0.8%, and
wherein a mass ratio (B2O3/RO) is in the range of 0.03 to 0.5,the mass ratio (MgO/(RO+ZnO)) is in the range of 0.17 to 0.8,
RO represents MgO+CaO+SrO+BaO, and
the glass is devoid of Sb2O3, ZrO2, and TiO2,

has a devitrification temperature of 1180° C. to 1235° C., and
has a strain point of 720° C. to 750° C.

US Pat. No. 11,065,333

ANTI-GLUCOSAMINIDASE PASSIVE IMMUNIZATION FOR STAPHYLOCOCCUS AUREUS INFECTIONS

UNIVERSITY OF ROCHESTER, ...


1. An isolated humanized monoclonal antibody or an antigen binding portion thereof that binds specifically to a Staphylococcus aureus glucosaminidase (Gmd) and comprises the complementarity determining region sequences of the VH domain of SEQ ID NO: 3 and the VL domain of SEQ ID NO: 10.
US Pat. No. 11,066,628

FERMENTED TEA BEER

Employee Brewing Company ...


1. A method for making a gluten-free and tea based fermented beverage for human consumption, the method comprising the steps of, in combination:steeping a form of tea leaves in water within a brewing kettle to form a tea;
wherein the tea leaves include a mixture of black tea leaves and green tea leaves;
removing the tea leaves from the brew kettle;
adding a form of yeast nutrient to the tea within the brewing kettle;
adding a fermentable sugar not derived from grain to the tea within the brewing kettle;
dissolving the fermentable sugar within the brewing kettle;
resting an unfermented mixture of the tea, the yeast nutrient, and the dissolved sugar, within the brewing kettle;
transferring the unfermented mixture from the brewing kettle to a closed fermentation tank where contents are not exposed to atmosphere;
knocking out the unfermented mixture by flash cooling the unfermented mixture to stop preparation of the unfermented mixture during transfer from the brewing kettle to the fermentation tank and aerating the unfermented mixture to add oxygen to the unfermented mixture during transfer from the brewing kettle to the fermentation tank;
wherein the unfermented mixture is flash cooled by passing the unfermented mixture through a heat exchanger during transfer from the brewing kettle to the fermentation tank;
adding a single culture brewers yeast to the unfermented mixture within the fermentation tank;
fermenting the unfermented mixture after the single culture brewers yeast is added to form fermented tea within the fermentation tank;
adding at least one of fruit puree, fruit jam, fruit jelly, and fruit juice to the fermentation tank prior to the step of fermenting;
aging the fermented tea within the fermentation tank when fermentation stops;
adding citric acid to the tea within the brewing kettle before the step of transferring the unfermented mixture from the brewing kettle to the fermentation tank and/or to the fermented tea within the fermentation tank after the step of fermenting;
filtering the fermented tea after the step of aging the fermented tea;
after filtering the fermented tea, adding stabilizers to the fermented tea to inhibit further fermentation;
after filtering the fermented tea, back sweetening the fermented tea by adding additional sweetener not derived from grain to the fermented tea; and
carbonating the fermented tea after the step of filtering the fermented tea.

US Pat. No. 11,067,914

LIQUID ELECTROPHOTOGRAPHIC INK(S)

HP Indigo B.V., Amstelve...


1. A liquid electrophotographic ink comprising:(A) a liquid vehicle;
(B) at least one colorant;
(C) a resin comprising an ethylene acid copolymer;
(D) an ethylene/(meth)acrylic acid C1-10 alkyl ester copolymer selected from the group consisting of an ethylene/methyl acrylate copolymer and an ethylene/butyl acrylate copolymer; and
(E) a condensation product of urea and aldehyde, wherein the aldehyde comprises formaldehyde.

US Pat. No. 11,065,853

POLYIMIDE FILM LAYERED BODY

TOYOBO CO., LTD., Osaka ...


3. A method for manufacturing a polyimide film laminate, the method comprising at least:(1) producing a silane coupling agent layer on a surface of a polyimide film; and
(2) superimposing 5 or more polyimide films after the production of the silane coupling agent layers, and applying heat and pressure to the superimposed polyimide films,
wherein all of the 5 or more polyimide films in the polyimide film laminate have the same composition.

US Pat. No. 11,066,629

LIPID METABOLISM-PROMOTING COMPOSITION INCLUDING ISOXANTHOHUMOL

SUNTORY HOLDINGS LIMITED,...


1. A method of promoting lipid metabolism by promoting fat burning, comprising: administering orally a composition for promoting lipid metabolism comprising isoxanthohumol,wherein the isoxanthohumol is administered to a human adult in an amount of 5 to 200 mg per 60 kg of body weight per day.

US Pat. No. 11,065,597

XENON ADSORBENT

TOSOH CORPORATION, Yamag...


1. A xenon adsorbent comprising:a zeolite having a pore size in the range of 3.5 to 5 ?; and

a silica alumina molar ratio in the range of 10 to 30, whereinthe xenon adsorbent comprises silver,
an ultraviolet-visible absorption spectrum of the silver measured after calcination of the xenon adsorbent at 500° C. in air has an absorbance peak in the range of 290 to 350 nm, andthe absorbance peak has a maximum value in the range of 310 to 330 nm.


US Pat. No. 11,065,337

COMPLEX COACERVATE FOR CONTROLLED RELEASE AND RELATED METHODS


1. A composition comprising a complex or coacervate of a polycationic polymer, a polyanionic polymer, FGF2, and IL-10 in amounts effective to reduce myocardial fibrosis in a patient following a myocardial infarction.
US Pat. No. 11,065,598

MERCURY CAPTURE USING FUNCTIONALIZED POROUS ORGANIC POLYMER WITH HIERARCHICAL POROSITY

University of South Flori...


1. A composition for binding mercury, the composition comprising a porous organic polymer (POP) comprising:(i) a plurality of repeat units having a structure according to the formula —CH2A1CH2— where A1 is a conjugated core having one or more heavy metal chelator moieties covalently attached thereto; and
(ii) a plurality of pores having a hierarchical pore size distribution over a range of pore sizes.

US Pat. No. 11,065,338

POLYSACCHARIDE THERAPEUTIC CONJUGATES

CASE WESTERN RESERVE UNIV...


1. A method for treating a retinal disease in a subject, the method comprising:administering to the subject in need thereof a therapeutically effective amount of a composition, the composition consisting of a polysaccharide and at least one retinoid linked to at least one monosaccharide subunit of the polysaccharide via a hydrolysable carboxylic ester linkage, the linkage being degradable by hydrolysis during digestion of the composition to provide controlled, delayed, and/or sustained delivery of the at least one retinoid upon enteral administration of the composition to a subject, wherein the at least one retinoid comprises a retinal derivative.

US Pat. No. 11,066,633

SYSTEMS AND METHODS FOR PRODUCING MICRO-ENGINEERED MODELS OF THE HUMAN CERVIX

THE TRUSTEES OF THE UNIVE...


1. A microdevice comprising:an upper microchannel comprising live cervical epithelial cells; and
a lower microchannel comprising a first parallel lane and a second parallel lane comprising stromal media, wherein the first and the second parallel lanes are lined with live vascular endothelial cells, wherein the lower microchannel further comprises a third parallel lane comprising a hydrogel, wherein the third lane is separated from the first and second parallel lanes by protrusion structures, wherein the protrusion structures are configured to pin menisci of a hydrogel precursor solution injected into the third parallel lane so that the lining of endothelial cells is formed immediately adjacent to the hydrogel.

US Pat. No. 11,065,600

USE OF A HEMOCOMPATIBLE POROUS POLYMER BEAD SORBENT FOR REMOVAL OF ENDOTOXEMIA-INDUCING MOLECULES

CYTOSORBENTS CORPORATION,...


1. A method of adsorbing endotoxins comprising contacting physiologic fluid with a polymer system comprising either polyol or zwitterionic functionality; said polymer system has the form of a solid support having a polymer coating comprising poly(diethylaminoethyl methacrylate), poly(dimethylaminoethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxyethyl methacrylate), poly(hydroxypropyl acrylate), poly (hydroxypropyl methacrylate), poly(N-vinylpyrrolidone), poly(vinyl alcohol), salts of poly(acrylic acid), salts of poly(methacrylic) acid, or mixtures thereof.
US Pat. No. 11,066,376

PRODUCTION OF PURIFIED DIALKYL-FURAN-2,5-DICARBOXYLATE (DAFD) IN A RETROFITTED DMT PLANT

Eastman Chemical Company,...


1. A process for the manufacture of a DAFD vapor comprising:a) mixing a furan-2,5-dicarboxylic acid (“FDCA”) composition and an alcohol compound in a mix zone;
b) feeding a furan-2,5-dicarboxylic acid (“FDCA”) alcohol mixture composition to an esterification reaction zone; and
c) in the presence of an alcohol compound, conducting an esterification reaction in the esterification reaction zone to react FDCA with said alcohol compound to form a crude diester composition comprising dialkyl furan-2,5-dicarboxylate (“DAFD”), said alcohol compound, 5-(alkoxycarbonyl)furan-2-carboxylic acid (ACFC), alkyl furan-2-carboxylate (AFC), and alkyl-5-formylfuran-2-carboxylate (AFFC); wherein said esterification reactor zone comprises at least one reactor, and wherein said reactor has been previously used in a commercial dimethyl terephthalate (DMT) process; wherein said alcohol has carbon atoms in a range from 1 to 3.

US Pat. No. 11,066,634

CULTURE DEVICE AND METHODS FOR ENUMERATING MOLD COLONIES

3M INNOVATIVE PROPERTIES ...


1. A method for enumerating mold microorganisms, comprising:contacting an aqueous fluid with a culture medium in a growth region of a thin film culture device to hydrate the growth region,
exposing aqueous fluid to a dry coating in the growth region;
incubating the inoculated culture medium for a period of time sufficient to form a macroscopically-detectable colony of a mold microorganism; and
counting a number of macroscopically-detectable colonies of mold microorganisms in the growth region; wherein
the growth region comprises(a) an effective amount of calcium-chelating compound,
(b) a nutrient medium capable of supporting the growth of a mild microorganism, and
(c) the dry coating, the dry coating, wherein the dry coating comprises ethylenediamine tetraacetic acid;

and wherein, when the step of contacting the growth region with aqueous fluid comprises inoculating the growth region with a colony-forming unit of a mold species, the calcium-chelating compound reduces a rate of lateral enlargement of the colony-forming unit growing in the culture device relative to the rate of lateral enlargement of a colony of the same mold species growing in an otherwise identical culture device that does not contain the effective amount disposed in the growth region;
without substantially delaying detection of the colony.

US Pat. No. 11,066,377

PROCESS FOR PRODUCING AROMATIC PRIMARY DIAMINES

RHODIA OPERATIONS, Auber...


1. A process for the production of an aromatic primary diamine, the process comprising reacting an aromatic dialdehyde, wherein the aromatic ring is a hydrocarbon ring, with hydrogen and ammonia or an ammonia-liberating compound selected from the group consisting of urea, uric acid, ammonium salts, symmetrical and unsymmetrical carbamates, carbaminates, semicarbazides, semicarbazoles, and aminium salts and organic/inorganic esters thereof, in the presence of a hydrogenation catalyst and an amine, wherein the molar ratio of the amine to the aromatic dialdehyde is no less than 1:4 at the start of the reaction.
US Pat. No. 11,066,635

METHOD OF CULTURING CELLS

Panasonic Corporation, O...


1. A method of culturing cells comprising:dividing a culture area into a center area and a plurality of peripheral areas, and designating the center area and the plurality of peripheral areas as measurement positions;
driving an observing unit to the measurement positions;
capturing and recording images at the measurement positions by an image measuring unit coupled to the observing unit;
calculating from the images by an image processing unit:a confluent rate at each of the measurement positions designated; and
an average confluent rate which is an average of sum of the confluent rates at the measurement positions designated, the confluent rate being defined as a proportion of an area occupied by cells in a designated area; and

determining a timing to perform a subculture of the cells, based on the confluent rate,
wherein the determining of the timing further includes determining when the average confluent rate is smaller than a first threshold value, the confluent rate of the center area is larger than a second threshold value, and the second threshold value is larger than the first threshold value; and
performing the subculture of the cells based on the determined timing.

US Pat. No. 11,065,341

DE-N-ACETYL SIALIC ACID ANTIGENS, ANTIBODIES THERETO, AND METHODS OF USE IN CANCER THERAPY


1. A humanized or fully human antibody that specifically binds a de-N-acetylated sialic acid (deNAc SA) epitope on an extracellularly accessible surface of a cancerous cell, the deNAc SA epitope minimally defined by a dimer containing at least one de-N-acetylated sialic acid residue having a free amine adjacent an N-acylated sialic acid residue or a sialic acid derivative residue, wherein:the antibody binds to the deNAc SA epitope on the surface of CHP-134 neuroblastoma cells, and
the antibody competes for binding to the deNAc SA epitope with an antibody comprising:a heavy chain polypeptide comprising:a VH CDR1 comprising amino acid residues 26 to 35 of SEQ ID NO:7,
a VH CDR2 comprising amino acid residues 50 to 66 of SEQ ID NO:7,
a VH CDR3 comprising amino acid residues 101 to 108 of SEQ ID NO:7; and

a light chain polypeptide comprising:a VL CDR1 comprising amino acid residues 24 to 39 of SEQ ID NO:3,
a VL CDR2 comprising amino acid residues 55 to 61 of SEQ ID NO:3, and
a VL CDR3 comprising amino acid residues 94 to 100 of SEQ ID NO:3.



US Pat. No. 11,069,983

MODIFIED Z-TYPE HEXAGONAL FERRITE MATERIALS WITH ENHANCED RESONANT FREQUENCY

Skyworks Solutions, Inc.,...


1. An enhanced z-type hexagonal ferrite having some barium atoms substituted for potassium atoms, the enhanced z-type hexagonal ferrite having a formula Ba3?xKxCo2?xM(III)xFe24O41, M(III) being a trivalent ion, x being 0
US Pat. No. 11,065,603

POROUS CARBON MATERIAL, METHOD FOR PRODUCING SAME, AND USE OF SAME

KURARAY CO., LTD., Kuras...


1. A porous carbon material comprising:a nitrogen content of 0.6 to 2.0% by mass;
a G band half-value width of 51 to 60 cm?1 and an R value of 1.08 to 1.40 measured in a Raman spectrum using a laser having a wavelength of 532 nm; and
iodine adsorption performance of 1000 to 1500 mg/g.

US Pat. No. 11,066,637

PARTICULATE STRUCTURE WITH A HIGH CONCENTRATION OF LIVE BACTERIA AND METHOD OF PREPARING THE SAME

TCI CO., LTD., Taipei (T...


1. A method of providing a bacterial solution with a high concentration of live bacteria, comprising(a) subjecting a bacterial strain to a three-stage fermentation to obtain a fermentation broth, wherein the three-stage fermentation comprises:subjecting a broth of the bacterial strain with a volume of V1 to a first fermentation stage for t1 hour to provide a first-stage fermentation broth, T1?2?t1?T1+2, and t1 is no less than 0.5,
diluting and subjecting the first-stage fermentation broth to a second fermentation stage for t2 hour to provide a second-stage fermentation broth, wherein the first-stage fermentation broth is diluted to a volume of V2, V2/V1=10˜35, T1?2?t2?T1+2, and t2 is no less than 0.5, and
diluting and subjecting the second-stage fermentation broth to a third fermentation stage for t3 hour to provide a third-stage fermentation broth, wherein the second-stage fermentation broth is diluted to a volume of V3, V3/V2=10˜35, T2?2?t3?T2+2, and t3 is no less than 0.5,

and wherein,
T1 is an initial time point of growth logarithmic phase of the strain, and
T2 is an initial time point of growth stationary phase of the strain; and
(b) concentrating the third-stage fermentation broth to provide a concentrated bacterial solution.

US Pat. No. 11,066,380

SALTS OF A HETEROCYCLIC COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF

Sunovion Pharmaceuticals ...


1. A salt, which is:crystalline (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine phosphate (Compound 1 Phosphate);
or a hydrate or solvate thereof.

US Pat. No. 11,066,638

METHOD OF PREPARING BACTERIAL GHOSTS FROM GRAM-POSITIVE BACTERIA BY HYDROCHLORIC ACID TREATMENT

PAICHAI UNIVERSITY INDUST...


1. A method of preparing bacterial ghosts of Listeria monocytogenes, the method comprising:providing Listeria monocytogenes as pathogenic bacteria for modification in order to provide a vaccine against a disease caused by L. monocytogenes;
subjecting L. monocytogenes to a treatment with hydrochloric acid for a period of 15 minutes at a concentration of 6.25 mg/ml at a temperature of 37° C. to form bacterial ghosts, which preserve envelopes of the L. monocytogenes and antigenic determinants present on the envelopes, whereby there is no DNA remaining in the bacterial ghosts and no live L. monocytogenes remaining in the culture; and
collecting the bacterial ghosts of L. monocytogenes having antigenic determinants present on the envelopes, such that the bacterial ghosts provide the vaccine against the disease caused by L. monocytogenes.

US Pat. No. 11,065,344

NANOCLUSTER CAPPED MESOPOROUS NANOPARTICLES, METHODS OF MAKING AND USE

KING ABDULLAH UNIVERSITY ...


1. A conjugate, comprisinga mesoporous nanoparticle having a plurality of pores, wherein the mesoporous nanoparticle is positively charged, wherein an active agent is disposed in the pore;
a plurality of metal nanoclusters, wherein the metal nanocluster has a negative charge, wherein a gate agent is lysozyme and the lysozyme is attached to the metal nanocluster;
wherein an electrostatic interaction causes the metal nanoclusters to seal in the active agent in the pore, wherein the gate agent is positioned on the outside surface of the conjugate so that it interacts with a gate target, wherein the active agent moves out of the pore upon removal of the metal nanocluster.

US Pat. No. 11,065,863

CEMENTED CARBIDE POWDERS FOR ADDITIVE MANUFACTURING

KENNAMETAL INC., Latrobe...


1. A powder composition comprising:a particle component comprising free flowing sintered cemented carbide particles having apparent density of at least 6 g/cm3 to 11 g/cm3 and a bimodal size distribution or multi-modal size distribution.

US Pat. No. 11,066,381

UROLITHINS-CONTAINING AQUEOUS SOLUTION, DRIED SOLID COMPOSITION THEREOF AND PRODUCTION METHOD THEREFOR, AND UROLITHINS STABILIZING METHOD

DAICEL CORPORATION, Osak...


1. A urolithin-containing aqueous solution containing urolithin and collagen,wherein the total amount of collagen is 0.1 to 100,000 parts by weight with respect to a total amount of 1 part by weight of urolithin.

US Pat. No. 11,066,639

METHOD FOR THE PRODUCTION OF A DAIRY FOOD PRODUCT AND A METHOD FOR GENE TRANSFER BY CONJUGATION

DSM IP ASSETS B.V., Heer...


1. A dairy bacterial strain with clumping and/or chaining properties when cultured under liquid conditions, wherein the clumping property results in clumps of at least 20 bacteria per average clump, and wherein the chaining property results in chains of at least 8 bacteria per average chain, and wherein the strain comprises an increased amount of expression product of a pilin gene cluster compared to that of Lactococcus lactis subsp. cremoris NCDO712 when cultured under identical conditions.
US Pat. No. 11,065,606

METAL-SUBSTITUTED BETA ZEOLITE AND METHOD FOR PRODUCING SAME

NATIONAL UNIVERSITY CORPO...


1. A metal-substituted beta zeolite comprising a product produced by a process comprising: subjecting, to ion exchange with ammonium ions, a beta zeolite of an alkali metal type produced without using any organic structure-directing agent; and then subjecting the zeolite to ion exchange with copper or iron(II) ions by a filter cake method.
US Pat. No. 11,066,640

MICROBACTERIUM SP. STRAIN AND METHOD FOR PRODUCING PSICOSE BY USING SAME

SAMYANG CORPORATION, Seo...


1. A method for producing psicose from fructose in the presence of manganese ion (Mn2+), comprising:contacting the fructose with a microbial cell of Microbacterium foliorum having psicose conversion activity to produce psicose from fructose, a culture of Microbacterium foliorum, a culture supernatant of Microbacterium foliorum, a culture extract of Microbacterium foliorum, and/or a lysate of Microbacterium foliorum,
wherein the Microbacterium foliorum has an increased psicose conversion activity in the presence of manganese ion (Mn2+) compared to absence of manganese ion.

US Pat. No. 11,065,346

RNA FOR USE IN THE TREATMENT OF LIGAMENT OR TENDON LESIONS

ethris GmbH, Planegg (DE...


1. A liquid composition containing naked RNA, wherein the RNA is solved in a glucose solution, and wherein the RNA is mRNA encoding a polypeptide selected from the group consisting of epidermal growth factor (EGF), platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), insulin-like growth factor 1 (IGF-1), transforming growth factor ?1 (TGF-?1), a growth and differentiation factor (GDF), Vegf, and bone morphogenetic protein (BMP).
US Pat. No. 11,066,641

METHOD FOR INDUCING DIFFERENTIATION OF CORNEAL EPITHELIAL CELLS FROM PLURIPOTENT STEM CELLS

Osaka University, Osaka ...


1. A colony consisting of concentric circular-like zones of different ectodermal cell lineages derived from induced pluripotent stem cells, wherein the concentric zones comprise a first zone consisting of neuroectodermal lineage cells, a second zone consisting of neural crest lineage cells and optic cup lineage cells, a third zone consisting of ocular surface ectodermal lineage cells, and a fourth zone consisting of surface ectodermal lineage cells.
US Pat. No. 11,066,899

METHODS OF SEALING A SUBSURFACE FORMATION WITH SAUDI ARABIAN VOLCANIC ASH

Saudi Arabian Oil Company...


1. A method of sealing a water-bearing subsurface formation comprising:introducing an activation solution comprising an aqueous solution, Na2SiO3 (sodium silicate), NaOH (sodium hydroxide), and one or both of CaCO3 (calcium carbonate) or Mn3O4 (manganese oxide) into a wellbore;
introducing Saudi Arabian volcanic ash into the wellbore, in which:introducing Saudi Arabian volcanic ash into the wellbore comprises introducing an ash solution comprising an aqueous solution and Saudi Arabian volcanic ash;
the aqueous solution comprises deionized water, tap water, fresh water, salt water, natural or synthetic brine, municipal water, formation water, produced water, well water, filtered water, distilled water, sea water, or combinations of these;
the ash solution comprises from 30 to 60 wt. % Saudi Arabian volcanic ash; and
the Saudi Arabian volcanic ash comprises SO3, CaO, SiO2, Al2O3, Fe2O3, MgO,

and K2O; and
allowing the Saudi Arabian volcanic ash to contact the activation solution in the wellbore, thereby forming a geopolymer barrier between the wellbore and the water-bearing subsurface formation and sealing the water-bearing subsurface formation.

US Pat. No. 11,065,347

METHODS FOR THE TREATMENT OF DANON DISEASE AND OTHER DISORDERS OF AUTOPHAGY

The Regents of the Univer...


1. A serotype 9 adeno-associated virus (AAV9) vector comprising a polynucleotide encoding lysosome-associated membrane protein 2B (LAMP-2B) operatively linked to a hybrid promoter comprising a chicken beta-actin promoter and a CMV enhancer (CAG promoter).
US Pat. No. 11,066,642

PREPARATION OF RETINAL PIGMENT EPITHELIUM CELLS

Cell Cure Neurosciences L...


1. A method of generating retinal pigment epithelial (RPE) cells comprising:(a) further differentiating a population of differentiating cells in a culture comprising a medium comprising one or more members of the TGF? superfamily, thereby generating a mixed population of cells comprising RPE cells;
(b) enzymatically removing said mixed population of cells from said culture without mechanical isolation of cells, wherein more than 10% of the cells of said mixed populations of cells are non-pigmented cells; and
(c) expanding said mixed population of cells to generate an expanded population of RPE cells.

US Pat. No. 11,065,348

APPARATUS AND METHODS FOR MAKING RECOMBINANT PROTEIN-STABILIZED MONODISPERSE MICROBUBBLES

The Trustees of the Unive...


1. A microfluidic device for generating microbubbles, comprising:(a) a substrate that defines a plane;
(b) a microfluidic channel system comprising a plurality of channels formed in the substrate and extending in the plane of the substrate along a surface of the substrate, the microfluidic channel system comprising:a plurality of fluid inlets,
at least one bubble formation outlet, the at least one bubble formation outlet comprising a nozzle having an adjustable diameter, the adjustable diameter of the nozzle effecting control over the size of microbubbles exiting the nozzle, and
a flow focusing junction in fluid communication with the plurality of fluid inlets and with the bubble formation outlet; and

(c) a dynamically actuatable valve that encircles the nozzle and is adapted to inflate and dynamically constrict the nozzle of the bubble formation outlet so as to change the adjustable diameter of the nozzle,
wherein the dynamically actuatable valve and the microfluidic channel system lie in the plane of the substrate.

US Pat. No. 11,066,643

NATURAL KILLER CELLS WITH ENHANCED VIABILITY, PROLIFERATION AND CYTOTOXICITY FOLLOWING CRYOPRESERVATION


1. An isolated population of natural killer (NK) cells that are thawed following cryopreservation and cultured without feeder cells in the presence of a CpG oligodeoxyribonucleotide (ODN) having a sequence identical to SEQ ID NO:1 at a concentration of 3 ?g/ml to 24 ?g/ml; and IL-12 at a concentration of 1 ?g/ml, wherein said NK cells were cultured without feeder cells prior to the cryopreservation.
US Pat. No. 11,065,610

FENTON-LIKE CATALYTIC MATERIAL WITH DUAL REACTION CENTERS AND PREPARATION METHOD THEREOF

NANJING UNIVERSITY, Nanj...


1. A method for preparing a Fenton catalytic material with dual reaction centers, comprising the following steps:(1) placing a nitrogen-containing compound in a corundum crucible, performing a first calcination on the nitrogen-containing compound in a muffle furnace and keeping a temperature to obtain a powdery carbon nitride; then dissolving the powdery carbon nitride in deionized water, and stirring to form a suspension solution;
(2) dissolving aluminum nitrate nonahydrate, copper nitrate trihydrate and glucose in deionized water to form a first solution;
(3) adding the suspension solution prepared in step (1) in a dropwise manner to the first solution to obtain a second solution, stirring the second solution uniformly and transferring the second solution to a polytetrafluoroethylene reactor for a closed hydrothermal reaction to obtain a product, and water washing, centrifuging and drying the product to obtain a solid; and
(4) drying the solid prepared in step (3), and then performing a second calcination on the solid in the muffle furnace to obtain the Fenton catalytic material with the dual reaction centers.

US Pat. No. 11,066,387

SALTS OF A PIM KINASE INHIBITOR

Incyte Corporation, Wilm...


1. A salt which is a hydrochloric acid salt of N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide.
US Pat. No. 11,066,644

METHOD OF PRODUCING NATURAL KILLER CELLS AND COMPOSITION FOR TREATING CANCER

NKMAX Co., Ltd., Gyeongg...


1. A cell therapeutic composition, comprising:a therapeutically effective amount of at least one of CD56+ and/or CD3?/CD56+ NK cells, wherein purity of the NK cells in the cell therapeutic composition is at least 90% relative to other cells in the cell therapeutic composition;
IL-2 at a concentration of 50-50,000 IU/mL; and
a pharmaceutically acceptable carrier,
wherein the cell therapeutic composition is in a form suitable for administration to a human patient in need of NK cell therapy.

US Pat. No. 11,065,611

EMISSION CONTROL DURING CATALYST REGENERATION

Monsanto Technology LLC, ...


1. A process for regeneration of a heterogeneous process catalyst comprising a chlorinated aromatic compound adsorbed thereon, the process comprising:desorbing at least a portion of the chlorinated aromatic compound from the heterogeneous process catalyst at a temperature no greater than about 350° C. prior to the step of heating the heterogeneous process catalyst at the temperature of from about 400° C. to about 1000° C. in the presence of oxygen to pre-clean the heterogeneous process catalyst;
heating the heterogeneous process catalyst having at least a portion of the chlorinated aromatic compound desorbed therefrom at a temperature of from about 400° C. to about 1000° C. in the presence of oxygen to remove at least a portion of the chlorinated aromatic compound from the heterogeneous process catalyst and produce a regenerated heterogeneous process catalyst and a regeneration effluent; and
contacting the regeneration effluent with an oxidation catalyst comprising at least one metal oxide selected from the group consisting of vanadium oxide, chromium oxide, manganese oxide, and mixtures thereof to form an oxidation effluent comprising carbon dioxide, water, and hydrochloric acid,
wherein the heterogeneous process catalyst comprises a zeolite.

US Pat. No. 11,066,645

ISOLATION AND CULTIVATION OF STEM/PROGENITOR CELLS FROM THE AMNIOTIC MEMBRANE OF UMBILICAL CORD AND USES OF CELLS DIFFERENTIATED THEREFROM

CELLRESEARCH CORPORATION ...


1. A cosmetic method comprising:topically applying to an intact skin surface of a human subject a cellular extract of mesenchymal stem/progenitor cells isolated from the amniotic membrane of human umbilical cord in liquid or viscous form, as an agent for promoting cell proliferation of skin keratinocytes and human dermal fibroblasts, wherein the cellular extract is in the form of a supernatant into which the mesenchymal stem/progenitor cells have secreted growth factors and peptides and wherein the mesenchymal stem/progenitor cells express the following genes:
POU5f1, Bmi-1, leukemia inhibitory factor (LIF), and secrete Activin A and Follistatin.

US Pat. No. 11,065,351

METHODS FOR DIAGNOSING AND MONITORING EOSINOPHILIC ESOPHAGITIS

University of Utah Resear...


1. A method of producing a medical image of an esophagus of a subject, the method comprising:orally administering radiolabeled heparin to the subject, wherein the radiolabeled heparin binds to one or more eosinophil granule proteins in the mucosal tissue of the esophagus; and
detecting the radiolabeled heparin to produce a medical image of the esophagus comprising one or more of a furrow, a ring, and a stricture along the esophagus.

US Pat. No. 11,066,389

PROCESS FOR THE MANUFACTURING OF MEDICAMENTS

Genentech, Inc., South S...


1. Crystalline (S)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one benzenesulfonate.
US Pat. No. 11,066,646

BROWN FAT CELL COMPOSITIONS AND METHODS

BIORESTORATIVE THERAPIES,...


1. A method of generating a population of human brown fat adipocytes, the method comprising:removing a human stem cell from human brown adipose tissue;
differentiating the human stem cell into a population of human brown fat adipocytes in a culture medium under a selective pressure of 0 to 5% oxygen, wherein the culture medium does not comprise a xenogenic animal product and comprises fibronectin type III domain-containing protein 5 (FNDC), insulin, dexamethasone, isobutylmethylxanthine, indomethacin, triiodothyronine (T3), rosiglitazone, and 0.5% to 20% human platelet lysate.

US Pat. No. 11,066,390

SOLID STATE FORMS OF IVOSIDENIB

ASSIA CHEMICAL INDUSTRIES...


1. Crystalline Form T11 of Ivosidenib, which is characterized by data selected from one or more of the following:i. an XRPD pattern having peaks at 14.3, 15.9, 21.2, 22.7 and 23.8 deg-2-theta±0.2 deg 2-theta;
ii. an XRPD pattern as depicted in FIG. 12;
iii. a solid state 13C—NMR spectrum with peaks at 178.4, 172.3, 151.8, 147.7 and 131.3 ppm±0.2 ppm;
iv. a solid state 13C—NMR spectrum having the following chemical shift absolute differences from a peak at 57.8 ppm±2 ppm of 120.6, 114.5, 94.0, 89.9 and 73.5 ppm±0.1 ppm;
v. a solid state 13C NMR spectrum having chemical shift difference from a peak at 178.4 ppm±1 ppm of 120.6 ppm±0.1 ppm;
vi. a solid state 13C—NMR spectrum substantially as depicted in FIG. 27; or combinations of (i)-(vi).

US Pat. No. 11,066,647

PLURIPOTENT HUMAN ADIPOSE ADULT STEM CELLS: ISOLATION, CHARACTERIZATION AND CLINICAL IMPLICATIONS

THE REGENTS OF THE UNIVER...


1. A method of ameliorating tissue damage in a subject, the method comprising administering a composition comprising pluripotent stem cells (PSCs) to the subject under conditions permitting the PSCs of the composition to divide and populate a site of tissue damage,wherein the PSCs are isolated from adipose tissue by a method comprising:
(a) releasing adipose cells, including an adipocyte fraction and a stromal vascular fraction, from an adipose tissue sample using a proteolytic enzyme that breaks the peptide bonds in collagen;
(b) co-incubating the released adipocytes and the released stromal vascular fraction for 2-36 hours, wherein 4-24 hours of said co-incubation takes place under stress conditions in a medium containing a proteolytic enzyme, in the absence of nutrients, under hypoxic conditions, and decreasing the temperature to 4° C.;
(c) recovering the viable cells following the co-incubation in step (b) by centrifuging to produce a cell pellet, removing supernatant containing adipocyte cell debris by aspiration, washing the cell pellet to remove the proteolytic enzyme, and resuspending the recovered cells in media.

US Pat. No. 11,066,649

METHOD FOR INDUCING HUMAN CHOLANGIOCYTE DIFFERENTIATION

INSTITUT NATIONAL DE LA S...


1. A method for inducing human cholangiocyte differentiation comprising the steps of:(i) providing a population of human hepatoblasts (hHB); and
(ii) culturing the population of hHB in at least one cholangiocyte induction medium to specifically induce cholangiocyte differentiation and produce a population of cholangiocytes, wherein the step (ii) comprises the steps of:
(a) culturing the population of hHB in a first cholangiocyte induction medium, wherein said first cholangiocyte induction medium is a chemically defined medium (CDM) comprising both growth hormone (GH) and epidemal growth factor (EGF), without human interleukin-6 or a variant thereof, and without sodium taurocholate hydrate or sodium butyrate;
(b) further culturing the population of hHB produced in step (a) in a second cholangiocyte induction medium according to step (ii), wherein said second cholangiocyte induction medium is the CDM of step (ii) to which is added human interleukin-6 (IL-6) or a variant thereof having at least 90% amino acid identity to the human IL-6 and at least 90% of the activity of the human IL-6; and
(c) further culturing the population of hHB produced in step (b) in a third cholangiocyte induction medium, wherein said third cholangiocyte induction medium is a CDM of step (a) to which is added sodium taurocholate hydrate and optionally sodium butyrate,
wherein steps (a), (b) and (c) are performed sequentially (a) to (c),

andwherein at least 60% of differentiated cells produced in step (ii) are cholangiocytes.

US Pat. No. 11,065,355

DEVICE FOR MONITORING EFFICACY OF A DECONTAMINATION PROCESS COMPRISING A BACTERIA CELL AND METHOD OF USING

3M Innovative Properties ...


1. A device for monitoring the effectiveness of a decontamination process, the device comprising:a substrate; and
a dry coating disposed thereon;wherein the coating comprises a plurality of bacterial cells of the Mycobacterium genus;
wherein the plurality of bacterial cells are Mycobacteria terrae cells;
wherein the coating comprises at least 1×106 CFU of the bacteria;
wherein the dry coating further comprises polyoxyethylene sorbitan monooleate.


US Pat. No. 11,066,650

METHODS FOR THE IN VITRO MANUFACTURE OF GASTRIC FUNDUS TISSUE AND COMPOSITIONS RELATED TO SAME


1. An in vitro method of inducing formation of a gastric fundus tissue comprising a functional fundic cell type, comprising the steps of:a) contacting a mammalian definitive endoderm (DE) cell with a wnt activator, an FGF activator, a BMP inhibitor, and retinoic acid, for a first period, wherein said first period is for a length of time sufficient to form a three-dimensional posterior foregut spheroid from said definitive endoderm;
b) contacting said three-dimensional posterior foregut spheroid with a growth factor, said Wnt activator, an EGF signalling pathway activator, said BMP inhibitor, and retinoic acid for a second period, wherein said second period is for a length of time sufficient to induce a fundic lineage comprising human fundic-type gastric organoids (hFGOs);
c) culturing said hFGOs of step b) with said wnt activator and said EGF activator for a third period;
d) culturing said hFGOs of step c) with said wnt activator, said EGF activator, and FGF10 for a fourth period;
e) contacting said hFGOs of step d) with a MEK inhibitor for a fifth period, wherein said fifth period is for a period of time sufficient to form said gastric fundus tissue comprising a functional fundic cell type.

US Pat. No. 11,066,651

METHODS AND COMPOSITIONS RELATING TO VIRAL LATENCY

UNIVERSITY OF UTAH RESEAR...


1. A method of screening for a composition that activates a cell latently infected by a virus; the method comprising the steps of:a) creating a latently infected cell using the method of comprising the steps of: a) isolating uninfected primary CD4+,CD27+, CD45RO— naïve T cells; b) priming the CD4+,CD27+, CD45RO— naive T cells toward differentiation, wherein at least a portion of the primary CD4+,CD27+, CD45RO— naïve T cells differentiate into non-polarized CD4+, CD27+, CD45RO+memory T cells; c) exposing the non-polarized cells of step b) to a lentivirus defective in env, wherein the lentivirus comprises one or more sequences of interest operatively inserted downstream of a lentiviral promoter, wherein the one or more sequences of interest are HIV genes that encode one or more HIV proteins, wherein the one or more HIV proteins comprise at least Tat and Rev, thereby creating a population of cells latently infected with the lentivirus; and d) stimulating the latently infected cells to reactivate the latent virus, wherein stimulating results in the expression of at least Tat and Rev;
e) exposing the cell to a test composition; and
f) determining if the latently infected cell becomes active.

US Pat. No. 11,065,357

WATER DISPERSIBLE FRAGRANCED FILM AND USE THEREOF

ROBERTET, INC., Budd Lak...


1. A fragranced film comprising, a film formed of a water soluble and/or a water dispersible polyvinyl alcohol polymer, wherein the film comprises a fragrance constituent absorbed or adsorbed onto a free-flowing particulate material based on a polysaccharide polymer which fragrance constituent includes one or more components which individually concurrently satisfy the following parameters:(a) a c Log P<3.00;
(b) a Vapor Pressure >0.1 mm Hg;
(c) a molecular weight of <180, and
where the said components cumulatively comprise not more than about 10% wt. of the fragrance constituent.

US Pat. No. 11,066,652

VACCINE FOR IMMUNOCOMPROMISED HOSTS


1. An isolated peptide that has at least 90% amino acid sequence identity with an amino acid sequence found within SEQ ID NO: 4, and has less than 10% amino acid sequence identity with a peptide found within SEQ ID NO: 8, wherein the isolated peptide is at least 8 amino acids and less than 50 amino acids in length, and comprises the amino acid sequence of any one of SEQ ID NOs: 34-37 and 39-41.